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This thesis portfolio includes two studies, a qualitative grounded theory of treatment 
adherence in people who inject drugs (PWID) and a systematic review of staff turnover in 
substance misuse services. The empirical paper is presented first, the findings of which led to 
the systematic review. The qualitative interview study arose from observations made within a 
clinical trial for the treatment of chronic Hepatitis C (HCV). The Chief Investigator of the 
ERADICATE trial team initially approached the Adult Psychological Therapies Service to 
investigate what seemed to be an anomaly – patient engagement with HCV treatment had far 
exceeded expectations. Indeed, positive treatment adherence is not common among PWID. 
What is more remarkable is participants continued the trial while experiencing the highly 
aversive side-effects of interferon, a medication known to mimic opioid withdrawal.  
It is important, if not crucial, to acknowledge the wider socio-cultural context in which 
this thesis portfolio was produced; the political landscape changed significantly over the course 
of writing. Divisive judgements about what characteristics make a person worthy and deserving 
of resources, became more dominant in public discourse and heightened the author’s awareness 
to these aspects in the data. PWID are among the most marginalised, and stigmatised groups in 
society. Several of the participants interviewed were homeless and all were at various points on 
a relapsing trajectory of injecting drug use. Perhaps positive treatment adherence in this 
population is counter-intuitive because intuition is often based on assumptions derived from 
implicit biases. Indeed, until 2008, Scottish policy systematically denied HCV treatment to 
PWID. Due to the assumption that re-infection was inevitable, treatment was seen to be 
wasteful. Epidemiological studies now show is that public health is significantly improved when 
PWID are treated, as population prevalence goes down.  
Completing this thesis led to an examination of fundamental assumptions, not just 
relating to the participants or the data, but also relating to the question of what Clinical 
Psychology is. What can we contribute to the science of human behaviour? How does a self-
aware mind arise and become autonomous? What leads adults to mentalize and enact their 
intentionality through particular behaviours, like taking medication? In grappling with these 
questions, the reader will detect the influence of developmental theorists, Vygotsky, Erikson 
and Bowlby. Seminal experiments, such as Tronick’s still face (Tronick, 1989)1 and Harlow’s 
monkeys (Harlow and Zimmerman, 1958)2, alongside newer fields of interpersonal neurobiology 
and developmental trauma have supplied the soil in which to ground the data gathered in this 
                                                          
1 Tronick, E.Z. (1989). Emotions and emotional communication in infants. The American Psychologist, 
44, 112–119. 
2  Harlow, H. F., & Zimmermann, R. R. (1958). The development of affective responsiveness in infant 




study. From our earliest days we are designed to absorb stimuli and integrate our perception 
into a gestalt. When PWID are characterised as “chaotic”, there is a failure to appreciate what 
this may really reflect: difficulty making sense of internal experience resulting in the absence of 
order, coherence and meaning. Therefore, the ontological presupposition underlying both the 
empirical paper and systematic review, is that humans are resilient, relational beings. When the 
correct conditions and contingencies are in place, our innate propensity to learn and grow can 
manifest in positive, adaptive behaviour.  
Narratives are not only ways of seeing the world, but ways of constructing it; we live 
through and are created by the stories told by others and ourselves (Murray, 2003)3. The public 
narrative of scepticism that has emerged around scientific endeavour, makes it all the more 
incumbent upon researchers to carry out their work with personal conviction, integrity and 
transparency (Rea, 2017, February 22)4. This qualitative analysis was completed with a high level 
of scientific rigour. Indicators of quality were employed throughout, for example, particular 
attention was paid to preserving the colloquial expression of participants in transcription and 
substantiates the authentic representation of their voice. 
The resultant grounded theory shows that the interpersonal context is a key part of 
adherence behaviour among PWID. This finding precipitated another question, if good quality 
relationships are important for patient engagement, how do staff stay engaged in the task of 
providing consistent, sensitive care on a sustained basis? The current evidence base on 
supporting and preserving compassion did not substantiate a systematic review, however, the 
opposite phenomenon, people leaving their jobs has been explored. As Clinical Psychologists 
we are able to connect with and influence different audiences by skilfully adapting our language. 
In order to appeal to managers and team leaders, the most pragmatic way of framing staff 
disengagement, was to examine actual staff turnover as a ‘hard’, concrete outcome. The 
methodological quality of studies included for review was reasonable in the context of 
methodological limitations. Findings point to the importance of collective support, good quality 
relationships and job satisfaction in mitigating against turnover in substance misuse services. 
This thesis portfolio is a sensitive and pragmatic understanding of engagement in both 
PWID and staff with the respective systems within which they are embedded. The results are 
contextualised and oriented toward medical colleagues working in HCV treatment, service 
leaders and fellow applied psychologists.   
                                                          
3 Murray, M. (2003). Narrative psychology. Qualitative psychology: A practical guide to research methods, 
111-131. 
4 Rea, S. (2017, February 22). Uncertainty perception drives public's trust, mistrust of science [webpage]. 









Chapter 1:  
A Grounded Theory of HCV Treatment Adherence in People who 
Inject Drugs 
Carolyn Maeve Butlerab,5, David Gillandersa , Kevin Powerb, and Kirsty Gillingsc 
a School of Health and Social Sciences, The University of Edinburgh, Teviot Place, Edinburgh, 
Scotland, UK, EH8 9AG. 
b NHS Tayside Psychological Therapies Service,  Dundee Health and Social Care Partnership,15 
Dudhope Terrace, Dundee, Scotland, UK, DD3 6HH. 
c NHS Fife,  Psychology Department, Stratheden Hospital, Cupar, Fife, Scotland, UK, KY15 5RR. 
 
(for submission to Harm Reduction Journal see Appendix VIII) 
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Background: Chronic Hepatitis C (HCV) is a significant public health threat largely 
affecting people who inject drugs (PWID). Positive antiretroviral treatment adherence is an 
uncommon and poorly understood phenomenon in this population. This study seeks to 
conceptualise this behaviour in a sub-sample of PWID who participated in a drug treatment 
trial for HCV.  
Method: Semi-structured interviews were conducted with fifteen participants who had 
demonstrated positive adherence within the ERADICATE HCV drug treatment trial. 
Participants had successfully attended weekly clinic appointments and complied with a self-
administered medication regime for a recommended duration. Participants engaged for an 
average of 21 weeks and were interviewed during the 3, 6 or 12 month follow-up period. 
Results: Analysis followed social constructivist grounded theory approach of open and 
focussed coding, categorising and theoretical comparison. Analysis was a reflective, reflexive 
process supported by the lead author’s journal writing, use of supervision and member-checking. 
The result is a pragmatic model of treatment adherence from a psychological perspective, 
charting the influence of intrapsychic, socio-cultural and interpersonal contexts on engagement 
and adherence. The theory outlines three key themes. These reflect the processes of moving 
away from states of mistrust, shame and guilt and moving toward trust, autonomy and 
connection. Adherence was captured as the culmination of hope, agency and purpose as 
emergent qualities. Analysis of the data was also informed by developmental perspective, 
conceptualising adherence as a dynamic, shifting process rather than a static outcome, as 
evidenced by the data.  
Conclusion: Findings should be considered by professionals working in substance misuse 
and those providing HCV treatment. The resulting theory supports a holistic understanding of 
the facilitators of treatment engagement and positive adherence. Logistical and structural 
aspects of service provision should maximise flexibility and access. Frontline workers should be 
supported by managers to provide consistent, sensitive, compassionate care through training 
and capacity planning. 
Keywords: HCV, hepatitis C, treatment, adherence, engagement, injecting, heroin, qualitative, 
interview, grounded theory.  






As a primary cause of liver related morbidity and mortality, chronic hepatitis C (HCV) is a 
global public health threat (Leask & Dillon, 2016). Over 185 million people are currently infected 
worldwide and the prevalence of liver cirrhosis in untreated patients is set to increase (Davis, 
Alter, Serag, Poynard, & Jennings, 2010; Hanafiah et al., 2013). In the UK, the demand for HCV 
related liver transplants is rising (Public Health England, 2014). Estimates predict that at current 
treatment rates, chronic HCV will lead to the death of one million people in the United States 
by 2060 (Rein et al., 2011). Moreover, HCV is now the most common cause of death in HIV-
positive patients on highly active antiretroviral therapy (ART) (The Antiretroviral Therapy 
Cohort Collaboration, 2010).   
The disease burden for HCV falls disproportionately on marginalised social groups (Rich et 
al., 2016). HCV prevalence is highest among people who inject drugs (PWID), with infected 
equipment representing a major route of transmission (Nelson et al., 2012). Before the 
enactment of the Hepatitis C Action Plan for Scotland II (The Scottish Government, 2008) 
intravenous drug use (IDU) was considered a contraindication for ART (see Health Protection 
Scotland, 2007). Treatment was withheld from this population based on the assumption that 
chaotic lifestyles lead to re-infection, thereby negating the outcome of successful treatment. 
This supposition has not been supported by empirical evidence; PWID have been shown to 
achieve as good, or better HCV treatment outcomes compared to other groups (Bojovic et al., 
2013). Epidemiological modelling studies have shown that the policy of ‘treatment as prevention’ 
has the potential to eradicate the HCV virus as population prevalence decreases when PWID are 
treated (Leask & Dillon, 2016).  
In the past decade, international and national clinical practice guidelines have adopted 
the position that there should be equity of access to HCV treatment for all patients. While the 
National Institute for Clinical Excellence (NICE, 2004) and European Association for the Study 
of Liver (Back, 2016) advocate that IDU is no longer a contraindication to HCV treatment, access 
remains poor and inclusion arbitrary (Martin et al., 2011). Within Europe, prevention strategies 
and coverage of HCV interventions continues to be highly variable (Aspinall et al., 2016). A UK 
audit showed that 10 out of 69 hospitals refused HCV treatment to all PWID (All-Party 
Parliamentary Hepatology Group, 2010). Further concerns have been raised regarding 
discriminatory attitudes and other factors which may impede the delivery of HCV treatment in 
drug and alcohol services (Treloar & Fraser, 2009). HCV has been described as a “changing 
epidemic” (Wandeler, et al., 2015), referring to the advent of direct-acting antiviral drugs that 




These new preparations are expensive however, and “high HCV treatment costs have stimulated 
an ethical debate on whom to treat and whom not to” (p. 730, Barth, 2015). The moral dilemma 
of resource allocation is compounded by a lack of guidance around the use of behavioural 
interventions to optimise adherence. This is a pertinent issue; despite technological advances, 
the adage that ‘drugs can’t work if people don’t take them’ remains true (Ho, Bryson, & Rumsfeld, 
2009). Sub-optimal adherence precipitates numerous adverse outcomes, including drug 
resistance (Afdhal, Zeuzem, Kwo, Chojkier, Gitlin et al., 2014).  Therefore, understanding 
adherence is crucial to maximising the success of efforts to contain and potentially eradicate the 
HCV virus.  
Adherence 
A standard clinical definition of adherence does not exist, though attempts have been 
made to unify the lexicon of terms used to describe medication use, including “compliance”, 
“concordance” and “persistence” (Cramer et al., 2008). Adherence has been operationalised as: 
the extent of patient conformity to recommendations given by the healthcare provider on “the 
timing, dosage, and frequency” of medication intake over a prescribed duration (p.46, Cramer 
et al., 2008). The qualitative evidence base on HCV treatment adherence has adopted a broader 
understanding of the construct by including barriers and facilitators of adherence behaviour 
(e.g. Sublette, Smith, George, McCaffery, & Douglas, 2015). Evon and colleagues (Evon, Donna, 
Golin, Bonner, Jason, Grodensky et al., 2015) related their findings from an interview study, to 
the Information-Motivation-Behaviour Skills (IMB) Model of Adherence (Fisher, Fisher, Amico, 
& Harman, 2006), which has been commonly used to conceptualise ART adherence in HIV. The 
IMB model posits that patients who are well informed about treatment, have internal and 
external motivation, and possess effective behavioural skills, will be more likely to adhere to 
treatment. The model has been critiqued for a focus on the rational synthesis of information, 
which has been shown to be an inconsistent predictor of behaviour and a lack of attention to 
the role of environmental and cultural factors in adherence (Sharma, 2012). 
Other studies have also drawn conclusions about the nature of adherence among PWID, 
with varying degrees of rigour. A meta-synthesis of qualitative studies examining HCV 
treatment adherence among PWID (Rich et al., 2016) reported a number of observations: (a). 
studies were heavily concentrated on populations in Australia and the USA; only one out of the 
ten studies reviewed was completed with UK based participants; (b). most studies did not 
describe their epistemological position, nor the interpretive stance of the researcher. Most 
referred loosely to a coding process that employed thematic analysis. Just one study referred to 
a “constructivist orientation” in their analysis (see Rasi et al., 2014); (c). two themes were 




health system factors, such as integrated services, and positive support from staff and peers. A 
third theme captured the role of the drug user identity as a source of struggle during treatment. 
(d). the Critical Appraisal Skills Programme (CASP) was used to appraise the quality of the 
research. Such structured approaches to evaluating qualitative studies have been found to be 
useful for judging procedural aspects of research in terms of methodological practice, but have 
been critiqued for being “less insightful and [making] weaker contributions towards the 
conceptual development” of an area (p.45., Dixon-woods et al., 2007). The lack of theoretical 
linkage between themes described by Rich et al. (2016) can lead to conceptualisations appearing 
disconnected and piecemeal. This is a limitation in the current qualitative research evidence 
base on HCV treatment adherence.  
Current Study 
Our understanding of adherence in HCV treatment has been developed principally from 
the perspective of public health medicine and sociology (e.g. Harris, Rhodes, & Martin, 2013; 
Treloar, Rance, Grebely, & Dore, 2013). In the latest publication from the European Monitoring 
Centre for Drugs and Drug Addiction, Harris and Rhodes, (2016) describe “enabling 
environments” as a framework for understanding engagement, initiation and access to HCV 
treatment. This integrative approach presents a rich outline of contextual forces that facilitate 
uptake of treatment. There is an opportunity to develop a unified understanding of positive 
HCV treatment adherence from a psychological vantage point, combining systemic and 
individual aspects. Researchers have called on Clinical Psychologists to apply their skills in 
formulating complex treatment issues to socially excluded groups (Maguire, 2015). The voices 
of PWID based in the UK are currently under-represented in the literature and extrapolating 
findings from different socio-cultural contexts is problematic. For example, the socioeconomic 
demographic, service provision model, and healthcare funding relevant to an Australian 
population differs from the UK (e.g. Sublette et al., 2015).  
To summarise, lack of rigour in the existing qualitative evidence base has resulted in a 
fragmentary understanding of treatment adherence, which lacks theoretical clarity. Therefore 
existing knowledge is more difficult to apply clinically, reducing the actual benefit to the patient. 
The current study adopted a robust epistemological position that supported pragmatism and 
integration in the field of qualitative HCV treatment research. This aim was achieved by 
focussing on positive adherence behaviour in a novel socioeconomic and treatment context, 
among cohort of PWID receiving HCV treatment in Scotland. The shortcomings of previous 







A qualitative methodology was employed for this study, using individual semi-structured 
interviews that were recorded and transcribed, then subject to grounded theory analysis. 
Treatment Context 
This study recruited participants engaged in the ERADICATE Hepatitis C drug treatment 
trial (International Standard Randomised Controlled Trials Registration: 
http://www.isrctn.com/ISRCTN27564683). The trial has been recruiting since 2013 and provided 
treatment using combination, pegylated interferon and ribavirin based therapy, to people 
actively injecting drugs. The overall “cure rate” (undetectable viral load at 3 month follow-up) 
for the whole cohort, in March 2017 was 84.5%. This is significantly higher than a pooled cure 
rate of 55.5% reported in a meta-analysis of 36 HCV treatment studies (Dimova et al., 2013). The 
trial is ongoing and is based at an urban Needle Exchange Clinic, co-located at a community 
centre offering intensive support programmes to the local substance misuse population in 
partnership with Local Authorities and NHS health boards. The trial regime required home-
based self-administration of antiviral medications on a daily basis, and attendance at weekly 
clinic appointments with one of two trial nurses, to receive an injection. The study used the 
following incentives: for each appointment attended, participants received a weekly supply of 
protein drinks and a £10 voucher for a large chain supermarket. At each appointment, 
participants underwent urine drug screening, viral blood count, pill counts and assessment of 
treatment side effects. 
Sampling 
To be considered for inclusion in this study, potential participants had to have 
demonstrated positive adherence by engaging in the treatment for the period recommended to 
achieve SVR (sustained virologic response, also referred to as “clearance”) within the 
ERADICATE trial (24 weeks for HCV Genotype 1 and 16 weeks for HCV Genotype 3)6.Nurses 
monitored medication adherence on a weekly basis by using pill counts and recording 
attendance at appointments. Positive adherence behaviour was demonstrated by 91.9% of the 
whole cohort, at the time of data collection (commenced in February 2016). This contrasts to 
discontinuation rates of up to 27% for similar clinical trials (Mulhall & Younossi, 2005). In 
consultation with the ERADICATE research team, the phenomenon of positive adherence was 
deemed to warrant specific investigation. Therefore, non-completers were not included, as they 
                                                          




represented a significant minority of the cohort and had not been contactable by staff after 
disengaging from the trial.  
In total, seventeen participants were approached to engage in the study; two agreed to 
participate but did not attend, and did not respond to subsequent attempts at contact from staff. 
Therefore, in-depth semi-structured interviews were conducted with fifteen trial participants, 
representing 88% of those approached, and 14% of the total trial cohort who had engaged (N=106) 
Following the initial identification of participants via purposive sampling (criterion-driven as 
indicated by the parameters of inclusion), theoretical sampling (data driven) was also employed. 
As several participants had spoken about their families, children and peers being relevant to 
their engagement in treatment, the partner of one participant who had also completed HCV 
treatment within the trial was recruited. This decision was based on data from three participants 
linking adherence behaviour to support from their partner. 
Data Collection 
Data were collected between February and April 2016, by the lead author. The two trial 
nurses and harm reduction staff within the Needle Exchange Clinic initially approached eligible 
trial participants, and provided them with an information sheet and a verbal description of the 
interview study. Those interested were invited by the clinic staff member to meet the Researcher 
on a one-to-one basis. Participants were assured that their anonymity would be protected, and 
that their responses would not have any influence on their relationship with any staff members, 
or subsequent treatment. If participants were agreeable, they provided their written consent to 
participate. Participants were given a £10 supermarket voucher for participating. Interviews 
lasted an average of 36.23 minutes (range = 21.43 - 46.33 mins.). 
A topic guide was used to support the interview conversation without compromising a 
neutral, exploratory approach to the unfolding of data (see Appendix I, p62.). Open questions 
were used to initiate dialogue e.g. “Tell me about your experience of the ERADICATE trial”.  
These were followed with prompts and probes to explore the content that participants offered. 
As data was collected and reviewed concurrently, associated and emergent issues were 
incorporated into subsequent interviews as per the grounded theory method (Charmaz, 2006).  
Analysis  
A social constructionist grounded theory approach was adopted as the epistemological 
stance to data analysis (Charmaz, 2006; Strauss & Corbin, 1990). Grounded theory seeks to 
explain how social structures and processes lead to  the emergence of phenomena through 




these elements (Strauss & Corbin, 1990). The approach is suited to conceptualising change 
processes (Morse & Johnson, 1991).  
Over nine hours of interview data were digitally recorded, transcribed verbatim, 
systematically coded and analysed. A minimum of two reviews of each script was undertaken. 
Textual data was coded in NVivo 11.0 software using the constant comparative method (Glaser, 
1978; Strauss & Corbin, 1990). Data was continually checked against previous data and relevant 
literature. A series of three steps informed the analytic process: (a) open, line-by-line coding, 
using all participants’ language without imposing preconceived interpretations (see Appendix 
III); 1,143 codes were generated at this stage. As the analysis proceeded, memo writing supported 
focused and higher order coding; (b) axial coding - clustering data to form abstract concepts 
and categories (see Appendix IV); and (c) theorising - generating an integrative explanatory 
framework by linking categories. A significant period of time was spent in immersion with the 
data and context, including clinic observations, discussion and liaison with members of the 
research team and extensive reflection on the process through the lead author’s journal writing. 
Each stage of the analysis was supported by monthly supervision, which included comparing 
codes and reviewing the development from line by line codes, to sub-categories, categories and 
overarching themes. The depth of discussion is demonstrated in post-supervision journal entries 
(see Appendix IV).  
In line with principles of good quality qualitative research (see Cohen & Crabtree, 2008), 
this study employed methods suggested by Mays & Pope (2000) to support the trustworthiness 
and credibility of the results: 
(i). Fair dealing: An iterative approach to data collection and analysis was employed. Data 
collection was continued until analysis indicated that theoretical sufficiency had been reached 
based on decreasing frequency of new axial codes and increasing abstraction. Alternative 
conceptualisations were considered for negative cases, which did not appear to fit with existing 
data. The construction of a theory is akin to producing a relational frame. Language acts as a 
bridge between the inner world of the participant and their external context. Therefore, quotes 
are presented in the actual vernacular of participants to enhance the authenticity of the themes 
being grounded in the data. Meanings and translations are provided where necessary to support 
clarity and coherence within the narrative.  
(ii). Triangulation: Data from multiple interviews was compared both within and across 
transcripts and codes to ensure comprehensiveness. The resultant grounded theory was 





(iii). Reflexivity: Reflective memos documenting the researcher’s process acted as an audit 
trail for decisions made regarding the analysis and to ensure no data was lost due to flawed recall 
or inaudibility of recordings. A selection of codes was randomly spot checked by a member of 
the research team. Differences in coding were discussed by returning to relevant extracts of raw 
data. A synthesised version of the analysis is presented; the full text is available via 
correspondence with the lead author. 
Results 
Participants  
All participants had demonstrated positive adherence by successfully completing the 
minimum period recommended for HCV treatment effectiveness within the ERADICATE trial 
(24 weeks for HCV Genotype 1 and 16 weeks for HCV Genotype 3). Four participants concluded 
treatment before the full duration of 24 or 16 weeks. In each case this was done under the 
guidance of the trial nurses, due to early SVR. Almost all participants had achieved SVR (N=14, 
93%). The one participant that did not achieve clearance had engaged fully for the 
recommended period (16/16 weeks). One participant completed an extra 12 weeks of treatment 
(24/16 weeks), an additional option offered within the trial, undertaken at the discretion of the 
participant. At the time of starting the ERADICATE trial, all were actively injecting drugs, no 
participant demonstrated liver fibrosis or high levels of cirrhosis and no participant had received 
HCV treatment previously. Participants were interviewed within the period of their three or six 
month follow-up. All participants identified as British Caucasian. The average age of the sample 
was 36 years old (ranging from 28-46). Two-thirds of the sample were male, which was 
approximately the same ratio as that of the larger cohort. The majority of participants were 
interviewed within the 3 or 6 month follow-up period after concluding the 16 or 24 week 
treatment (N=13, 87%). Eight participants reported a forensic history and none were in paid 
employment. Other characteristics of the sample are outlined in Table 1. 
Grounded Theory 
This grounded theory outlines a trajectory of behaviour change, in which participants 
shifted between contrasting positions. The data that emerged moved from an exclusive focus on 
HCV treatment adherence to incorporate the meaning of the HCV virus to participants. The 
resulting grounded theory conceptualises HCV treatment adherence within the framework of 
three overarching core themes: hope, agency and purpose. These reflect the qualities that 
emerged from the reconciliation and resolution of opposing forces (sub-categories). The specific 














Demographics Health  





No. weeks engaged 





Stage of Treatment 
Follow-up at 
Interview 
1.  “Laura” 41.36 30 F Independent Y 13/16* 3 3 month  
2.  “David” 46.33 43 M Independent Y 24/24 1 3 month 
3.  “Matt” 38.24 46 M Independent Y 24/24 1 3 month 
4.  “Jack” 33.30 40 M Homeless-street Y 21/24* 1 6 month  
5.  “Dean” 40.22 34 M Hostel Y 24/24 1 3 month 
6.  “Rick” 46.51 33 M Independent Y 24/24 1 3 month 
7.  “Sean” 45.55 44 M Independent Y 24/24 1 6 month 
8.  “Peter” 43.11 41 M Independent Y 8/16* 3 3 month 
9. “Will” 21.43 31 M Hostel Y 24/16 3 12 month 
10.  “Mike”^ 40.10 38 M Family Y 24/24 1 6 month 
11. “Zara”^ 22.09 36 F Family Y 24/24 1 12 month 
12.  “Gemma” 37.50 33 F Independent Y 24/16 3 6 month 
13.  “Lisa” 40.41 30 F Independent Y 24/24 1 3 month 
14. “Walter” 21.50 28 M Independent Y 18/24* 1 6 month 
15.   “Sarah” 25.04 35 F Hostel N 16/16 3 3 month 
   Table 1. Sample Characteristics  *Early responders ^Two participants linked as partners 
                                                          









Theme I: Letting Go and Letting In 
The first main theme outlines the process of letting go of mistrustful perceptions, and allowing 
faith and hope to be placed in the trial nurses and the treatment.   
Mistrust: 
The social world of PWID is characterised by mistrust, with persistent risks of harm, 
victimisation, and exploitation. There is a latent expectation that others behave disingenuously 
and inconsistently which leads to defensiveness and detachment: 
“I don’ really associate wi’ people abou’ here, they’re all two faced” (Zara) 
The majority of participants spoke of isolation; the view that “I've got no one” (Peter) was 
common and entrenched. Furthermore, the peer context constructed treatment as a harrowing, 
distressing process, creating a subjective norm that treatment was “brutal” (Walter). When 
asked “How confident were you in the treatment?”. Mike responded: 
“Oh I wasn't no … I'd heard a lot 'a y'know in drug circles … all these different horror stories 
‘oh that treatment was hell it was the side-effects was really bad an' it didn' work an' I only 
lasted three weeks’” (Mike) 
“Good enough” care:  
The theme of mistrust contrasted sharply with participants’ perception of the trial nurses and 
how they felt they could trust them: 
“They're no people tha' are gonna lie to yer face so 'ken it kinda makes it like … you trust 
them” (Dean) 
Confidence in nurses’ ingenuity and positive intention was key to unlocking participants’ 
openness and willingness to engage in treatment. Speaking about his lack of understanding of 
the virus and treatment, Dean states, “I dinnae ha' (did not have) a clue wha' they were on abou'. 
The capacity to let go of the “horror stories” surrounding treatment and consider the possibility 
of clearing the virus, was related to a felt sense of the nurses’ integrity and transparency.  
“I 'ken'd (knew) tha' wha'ever they done to us 'ken (you know) it was for a good reason” 
(Dean) 
Nurses’ portrayed a number of personal qualities and behaviours that provided the stimulus for 
participants to engage with them. Salient features of this interpersonal context were safety, 
consistency and sensitivity. Interactions were imbued with kindness and unconditional positive 




and disclose personal experiences. Non-judgemental responses were particularly important as 
most participants were engaged in ongoing IDU: 
“They would never ever look down at ya if say for instance you were going through your Hep 
treatment and you used heroin they would never be like that’s a waste yer treatment” (Laura)  
 
Receiving interpersonal warmth and being listened to, had a powerful, humanising impact in 
worlds deprived of connection:  
“They [the nurses] jus' make you feel like a nor- like a human bein' and when I was at the 
stage when I didn't feel like a human bein' I didn't feel like part of the society an' things ay” 
(Sean) 
Nurses were available on a consistent basis, in person and remotely by mobile phone, under the 
proviso of an open invitation for contact. Participants were confident in receiving a prompt 
response and believed that “they're helpful an' they're there if you need them” (Sally). The 
experience of sensitive responsivity led participants to develop an expectation of care that was 
reliable and safe.  
HCV was perceived to be more treatable than other blood borne viruses, as “it's not like HIV” 
(Sally). Further exploration of confidence in initiating treatment however, revealed ambivalence 
and low expectation among some participants: 
“I jus' had to wait an' see … I mean it could work an' it migh’ no work” (Sally) 
“I probably looked on the negative side … so I wasn' settin' mysel' up for a fall if it didn' work” 
(Sean) 
Others stated that just knowing “there was a treatment available an' it gave me a chance of gettin' 
rid of it” (Rob) was enough to undertake treatment. This variability indicates that the willingness 
to undertake treatment was not fully accounted for by intellectual perceptions of treatability, 
but also by the felt sense of hope instilled by the care provided. Concrete knowledge was 
secondary to the faith derived from the relationship with staff: 
“[the nurses] like tellin' us about it they never says it was a hundred percent bu’ I put my 
trust into them … I trusted that it worked” (Lisa) 
Theme II: Showing up and Enacting Agency 
The second main theme outlines the process of mentally and physically ‘showing up’ for 
treatment. This required the reconciliation of painful feelings, particularly shame and stigma, 
to enact personal agency and autonomy in the form of adherence behaviour.  
Shame:  
The diagnosis provoked a feeling of being less than, worthless and powerless; for Peter it was 




diagnosed, he felt “absolutely gutted felt disgusted wi' myself felt dirty jus' ashamed 'a mysel’” 
(Jack). Language used by participants to refer to the HCV virus conjured images of ‘dirt’, decay, 
and degradation, synonymous with IDU. Rob stated that HCV is “a junkie’s disease” (Rob). 
Positive status was linked with the stereotype of PWID as irresponsible, chaotic and careless:  
“Jus' comes wi' a kinda stigma does it 'ken Hep C ay dirty junkie sits an' shares needles all 
the time sit in basement flats or drug dens an' jus' pass the needles aroun'” (Jack) 
 
The virus was understood as an ‘other’ that invaded and sullied the self-concept. Participants 
expressed the drive to “get rid of” this part as a means of countering shame.  
Stigma and un-deserving: 
PWID experience stigma within micro and macro level social contexts. Rob plays “devil’s 
advocate” by espousing popular attitudes to funding HCV treatment for PWID; this evocation 
is underlined by internalised, or self-stigma: 
“Why should we pay to cure drug addicts ‘a Hepatitis jus’ for ‘em to continue usin’ drugs 
anyway” (Rob) 
Fear of stigma from others prevented some participants from disclosing their status. This burden 
to live in secrecy, perpetuated shame by provoking feelings of incongruence:  
“None of my friends knew that I had it am… I jus’ couldn’ tell them that I had it cos’ I was 
ashamed of myself that I caught it” (Laura) 
Due to misperceptions around the communicability of the virus, Laura’s family imposed 
restrictions on her to minimise the perceived risk of transmission, leading to physical and 
emotional segregation: 
“It didn’ just feel right like not being able to put my cup beside my family’ cups and cutlery 
I put [them] in the cupboard wasn’ allowed to put it in the drawer” (Laura) 
For PWID, stigma appears to extend beyond the kitchen table, it is wound and bound into our 
socio-political fabric. PWID are embedded in political structures and internal procedures that 
uphold contingencies of deservedness. The data describes that PWID are subject to pervasive 
societal narratives about their ‘worth’. Matt’s account speaks to ideals of equality in treatment 
access, as demonstrated by the inclusion of those currently injecting drugs in the trial: 
“It shows the government tha' y'know people still everybody matters y'know wha' I mean it's 
not just people that's maybe in recovery” (Matt) 
The physical and emotional struggle:  
Side effects were a challenging aspect of HCV treatment and frequently initiated a conflict 




“It was on occasion I felt like jus' sayin' nah I I I cannae do this this is too painful … bugger 
this I need'a stop cos I cannae do it” (Mike) 
Skin irritation, extreme fatigue, hair thinning, cold/flu symptoms were included in a long list of 
symptoms experienced. The fortified protein drinks provided as an incentive for attending 
appointments were typically used for meal replacement where gastro-intestinal issues caused 
significant appetite and weight loss. Side-effects precipitated a lack of normality and 
unpredictability, which could be frightening and made life “mair chaotic” (Mike). Physical 
withdrawal and disengagement were strategies used to manage pain, low mood and suicidality, 
exacerbating feelings of disconnection and isolation. Nurses offered a compassionate, validating 
response by normalising side-effects: 
“I was noticing like hair falling out an’ they would they would make you feel like didn’ worry 
about it it’s ok it happens to everybody it’s not just you” (Gemma) 
Personalised education and empowerment:  
Explicit explanations of the treatment procedure, phlebotomy skills and timely individualised 
feedback on viral load were valued by participants. Walter appreciated how “they [the nurses] 
was on top a’ things keepin’ me informed” (Walter). The provision of education was important 
for challenging stigma, for example, Laura brought her mother to clinic and nurses corrected 
misinformation about the risk of transmission. Information could also have the opposite effect; 
some participants said they “purposely didn' want to know abou' side-effects” (Walter) as they 
anticipated that this would negatively influence their experience of the medication: 
“A lotta people'll read up about it .. an' then all of a sudden they've got some 'a them (side-
effects) … so I didn't want none 'a tha'” (Matt) 
Safety and discretion: 
The centre has a widely respected reputation for providing specialised professional support to 
PWID. While Lisa felt she could relate to “people obviously goin’ through the same as what I was” 
(Lisa), other participants, attempting to abstain from IDU valued discretion and anonymity: 
“If yer tryin' to stay eway fre' drugs it's no easy go into tha' place [other substance misuse 
service] an' there's people sittin' takin' drugs … whereas when you come in here there's not” 
(Sally) 
 
“Naebody'd even 'ken wha' I'd even been here for 'ken so … it seemed easier tha' way” (Dean) 
The clinic was located in a separate part of the building with a concealed entrance. This 
maximised privacy, minimising the risk of exposure and accompanying sense of vulnerability. 
The importance of this ergonomic aspect was reinforced by participants commenting on their 




not only more anxiety provoking by design, but was also associated with distressing memories 
of being judged for IUD. Gemma predicts that she would have disengaged from hospital based 
treatment, due to feeling shame, a contrast to how she felt at the centre: 
“If I had to start tha’ at the hospital I don’t think I woulda went all the way through … I 
wouldn’ went back” “at the hospital I would feel embarrassed an’ ashamed an’ stuff but here 
I didn’” (Gemma)  
 
Holistic needs-led support:  
When support needs were systemic and pragmatic, nurses helped participants to resolve basic 
welfare issues by ordering food parcels and liaising with criminal justice services to facilitate 
treatment access. The trial clinic was co-located with harm reduction services, therefore many 
participants were already acquainted with the setting and the staff. The treatment was run with 
a collective team approach. Liaison and information sharing facilitated unified and continuous 
care. The staff within the centre acted as a ‘home base’, a source of containment of emotional 
states: 
“If you were havin’ like a bad day you know that if you were comin’ in … you could talk to 
them” (Lisa) 
Flexibility and access:  
A short wait to treat and drop-in appointment systems, comprising open slots and no ‘did not 
attend’ policy, supported attendance at appointments. This meant participants had a greater 
sense of ownership, and control over their engagement. Will captures the sentiment of many in 
stating, “it was a lot easier bein’ a drop-in” (Will). There is a balance however between specificity 
and openness, restriction and freedom. While the flexibility of the drop-in system was important, 
the expectation that the clinic “always” being “every Thursday” (Jack) supported a sense of 
stability and predictability. The city centre location and accessibility by public transport were 
practically helpful, though two participants actively choose to come to the centre, rather than 
the hospital, attributing this to familiarity and trust, rather than convenience: 
“I know the clinic I know the staff here … I mean like [the local hospital] is like 5 minutes 
from ma house [laughs]” (Zara) 
Structured social contact and esteem:  
For participants who were otherwise disengaged from any kind of structured activity, attending 
treatment appointments provided an opportunity for social contact which improved mood. 
Mike conceptualises his own and his partner, Zara’s attendance at the centre as an opportunity 




“She [Zara] says "nah I like to get oot an' come doon an see them" an' then tha' was like 
maself … it kinda lifted ma spirits” (Mike). 
Multiple health and welfare services were available at the centre including a dental service, and 
a “recovery cafe”. Gemma speaks of the interpersonal support she received from a group she 
attended at the centre during treatment: 
“It was people to speak to an’ never judged ya’ they sorta understood listened to ya’ … that 
did help me that group I needed that” (Gemma)  
Within the PWID community itself, treatment was held in a kind of mysterious esteem which 
roused the interest and curiosity of others. Those few participants who disclosed that they 
received treatment were awarded with kudos and status by their peers. They were viewed as 
experts-by-experience, and stepped into this authority to advise others: 
“A lot 'a them asked wha' happened an' how does it work … an' I had to explain” (Peter) 
Theme III: Moving with Purpose 
The third main theme outlines the process of channelling feelings of guilt and obligation into 
personal purpose, by embracing treatment as means of moving toward values and connection.  
Guilt and obligation:  
Some participants expressed a remorseful stance in relation to acquiring the virus. Guilt, as 
distinct from shame and self-stigma, had a more explicit other-orientated dimension. It arises 
from a moral transgression, a violation of a basic expectation that results in harm to another. 
Fear of transmission was a particularly striking source of self-blame in the narrative of 
participants who were parents:  
“If my son caught that I wouldn’ be able to live wi’ myself so that’s why I’m doin’ it and 
finishin’ it” (Laura) 
Successful treatment functioned as a means of stepping back from the PWID identity, and 
repairing the self-concept as a “good enough” or at least “un-defective” caregiver. For some, this 
was with a view to the possibility of recovering lost relationships with estranged children: 
“I had it in my head tha' I get rid 'a the Hepatitis I come off the drugs I kick-start my life 
again eh an' I get … back into my son's life aswell” (Matt) 
Lisa speaks of the obligation and duty of care she feels towards her eight month old son in foster 
care. For Lisa, undertaking treatment acted as a proxy for giving care, as she could not do this 
in an immediate way:  
“My son he’s he’s no’ actually stayin’ wi’ me … so the way I seen it is if I end up no’ well whose 





Family and health were the two most salient values motivating participants: 
“The only reason I wouldde do it is fer my kids if I never had anything else cos I've not got 
nothing else in m'life” (Peter) 
Parenting with HCV is a tiresome, weary task. Paranoia and hypervigilance characterised 
physical interactions with children, as many parents employed the strategy of limiting physical 
proximity to manage the perceived risk. This bodily separation precipitated a distressing sense 
of estrangement. Clearance was a means of obtaining normality as a caregiver: “being able to 
take ma son out an’ jus’ do normal things wi’ ‘im” (Laura). Participants were concerned about the 
impact of a shortened lifespan or poor health upon their family. Witnessing others visibly ill 
from HCV-related morbidity instilled an awareness of personal mortality which reinforced the 
motivation to complete treatment: 
“What was important about getting treated?” 
…  I've seen a few people die wi' cirrhosis 'a the liver yea an' it's not a very nice way to go... 
tha' was the reason” (Sean) 
Sean later hypothesises that taking action to engage in treatment would prevent dependency on 
his children in later life. This was not a universal motivator however, as some participants 
indicated little understanding of the medical complications of untreated HCV. 
Response-ability and connection:  
Participants intentionally prioritised treatment over other competing demands. To prevent 
missed doses medication was systematised and routinized into a stable regime. Treatment 
engagement was not only an act of autonomy but a manifestation of maturity and reciprocity, 
where the self, and others, are respected through consciously chosen action. Responsible self-
care behaviour arose from a sense of reciprocity: 
“Their attitude aye really nice people [the staff] like I say so .. felt like I'd be lettin' them 
down if I dinnae turn up” (Jack) 
Connection to a supportive interpersonal context (treatment trial staff, spouses, friends or 
children) provided a social context that supported positive treatment adherence. Availing of 
practical support was a manifestation of healthy reliance, which included assistance with logistic 
concerns such as access to the pharmacy. Emotional encouragement promoted resilience and 
commitment: 
“My missus she was like tha' look stick in y'know you you could do it’” (Mike) 
“They (the nurses) encouraged us aye … ‘yer doin' well’ … ‘keep goin' 'ken’ … an' sorta cheer 




Clearance provided permission to engage with others in a more intimate way, with “nothing to 
hide” (Gemma). The trial itself offered a means of being part of, rather than outside an in-group. 
There was a sense of belonging, connectedness and pro-social group identification. Matt 
identifies how he began to relate to the staff in a way that transcended traditional professional-
service user roles. The culture of the centre mitigated the power imbalance between professional 
care provider and client, and promoted a sense of equity and equality. This was achieved 
through the use of humour, laughter and light-hearted dialogue: 
“I think that's wha' their a lotta their remit is …  they've got a buddy ethos … likes 'a you 
come it's buddy buddy it's no staff client” (Matt) 
Opportunity and purpose:  
Completing treatment was a “goal”, a source of achievement which produced feelings of relief, 
joy and success. The vouchers and fortified drinks were conceptualised as “rewards” which 
positively reinforced and incentivised attendance at appointments. In this way, treatment was 
a scarce opportunity to succeed at something, to be recognised and validated for the investment 
of effort. 
For some, HCV treatment was part of moving on from drug addiction, and was a “kick start” to 
fulfil personal potential and lead a more meaningful life. Matt captures the paradox that stability 
in his living conditions allowed him to contemplate the future in a flexible way and enact value 
led behaviour through volunteering in the community:  
“I'm layin' roots”, “now I'm stayin' in one place I'm movin' forward” (Matt) 
In a world where PWID are accustomed to rejection and judgement, some expressed gratitude 
for this rare experience of being valued and cared for: 
“I couldn' have asked for anything better for (than) wha' they've done f'ma (for me) 'ken 
because … it's easy enough for people to turn you away” (Dean) 
 
Discussion 
Contextualising the Grounded Theory  
This grounded theory proposes a developmentally informed, contextual framework for 
HCV treatment adherence. The socio-cultural context of the population, and the conditions of 
the trial emerged as an important feature of treatment adherence. Adherence is a dynamic 
process, whose underlying function, rather than form, should be understood. “Motivation” and 




theory captures the role of human psychology in the reorientation from a stuck, marginalised 
position toward an expansive, valued life direction.  
The social milieu of HCV is one of interpersonal deprivation and exclusion which is 
reinforced and perpetuated by societal institutions and the individuals who comprise these 
institutions (Cockersell, 2015). PWID identify with and are identified by the collective noun 
“junkies”, conjugated from “junk”: discarded articles that are considered useless or worthless. 
The conceptualisation of the HCV virus as “a dirty junkie’s disease” not only echoes derogatory 
colloquialisms used to refer to PWID, but may also be a projection of internalised self-disgust 
and shame. Alienated, rejected mind-sets are shaped at the interface between the social and 
individual; as is the potential for behaviour change. The processes which precipitate and 
maintain adherence: hope, agency, autonomy, purpose and connection are scaffolded by good 
enough care that facilitates psychological safety. At the root of these qualities, secure relational 
bonding has a reparative impact on the effects of complex trauma, stigma and isolation, to 
enabling a sense of value and purpose to emerge, from which health behaviour change follows.  
Findings concur with existing literature that posits the patient-provider relationship as a 
critical mechanism in treatment engagement and medication adherence (Evon, et al., 2015; 
Stewart, Mikocka-Walus, Harley, & Andrews, 2012). The need to be valued, to be heard, to 
belong, to achieve and to have meaning are considered universal and primal (Seager, Phipps, 
Murphy, & Barker, 2017). The care provided within the ERADICATE trial not only treated the 
HCV virus as a medical condition but also met the psychological needs of participants. When 
these needs were met sensitively and sufficiently, participants could expand their behavioural 
repertoire and demonstrate this in mature and responsible ways. The skill of staff was to 
interpret and respond to participants with compassion, authenticity and humanity. One 
interpretation is that the centre provided a physical and mental representation of a both a “safe 
haven” and “secure base”, a point of stability and security where fears could be “housed” and 
contained. The outcome of this was development of agency, referring to participants’ subjective 
awareness that they can initiate, execute, and control one’s own actions in the world, and 
channel this into performing independent self-care behaviour. The fact of being part of a 
research trial may also have functioned as an in-group identity: participants were part of a bigger, 
meaningful unit that others regarded with respect. Under these conditions, participants could 
mobilise as autonomous agents, able to make flexible, intentional choices i.e. attending the 
drop-in clinic and sustaining a daily self-administered medication regime. Other studies also 
support the finding that HCV treatment adherence is strongly influenced by service accessibility, 




Previous qualitative studies have documented how negative cognitive evaluations, such 
as fear of side-effects or procedures can lead participants to avoid HCV treatment, whereas 
confidence in a cure promotes adherence (Sublette, Smith, George, McCaffery, & Douglas, 2015). 
Similarly, the Information-Motivation-Behaviour Model espoused by Evon, et al. (2015), places 
an emphasis on information-processing as a primary determinant of adherence behaviour. 
While this study shows that education can be supportive and empowering (e.g. challenging 
stigma by correcting assumptions among family members), the focus on the content rather than 
the context of knowledge provision is incomplete. Beyond intellectual appraisals, adherence 
behaviour encompasses deeper intrapsychic processes situated in a relational context. In this 
sample, confidence in the efficacy of the medication itself was variable and knowledge of the 
virus and side-effects were highly aversive, but did not trigger avoidance. From a developmental 
perspective, the receipt of transparent explanations of treatment and the setting of expectations 
relating to adherence may have served a regulatory and containing function for these 
participants, rather than what was said about the medicines per se. This would explain why, 
rather than being overwhelmed and immobilised by the guilt of contracting the virus, 
participants embraced their obligation and duty of care. Living with the risk of transmission to 
a child was a violation of the perceived role of a parent as a protector. This awareness enabled 
participants to tolerate side-effects with acceptance, in the service of what they truly valued: 
health and family. Paradoxically, increased self-efficacy scaffolds healthy, interdependent 
behaviour. The effective use of support from partners and family outwith the trial and centre is 
a sign of psychological maturity, marking a shift from the shame, isolation and vulnerability that 
characterised positive HCV status, towards effective help seeking. Despondent narratives of dirt, 
disgust and rejection pose a contrast to actual behaviour that demonstrated responsibility, 
worthiness and reciprocal connection. The provision of fortified drinks not only reinforced 
behaviour as a reward, but also symbolised the values underlining the trial, that PWID with 
HCV are deserving of care. 
Strengths and Limitations 
This study only recruited participants who had demonstrated positive adherence 
behaviour. The reported findings focus on sustained engagement rather than initial treatment 
uptake. This lends a quality of homogeneity and specificity to the sample, which has enabled 
the theory of adherence to emerge faithfully. This study has also uniquely captured the meaning 
of contingency management (receiving drinks and shopping vouchers for adherence behaviours) 
in the context of treatment engagement. While data was self-reported, liaison with the trial team 
facilitated verification of clinic activities and descriptions. This study did not recruit participants 
that had disengaged from treatment, as these participants were a small proportion of the whole 




trial group regarding positive adherence. However, this may reflect a limitation as the grounded 
theory may not be wholly applicable to PWID who are not engaged in any healthcare services. 
While a theoretical sampling method was employed, participants were recruited by staff who 
knew them previously from working within the Needle Exchange Clinic. This possibly increased 
the risk of sampling bias as staff members may have been more likely to approach certain 
participants for recruitment, depending on their attitude towards, and familiarly with different 
individuals. More males than females participated, however, this reflected the gender 
distribution of the full cohort. The findings of this study were generated from patients 
participating in a drug treatment trial based in the community, so may not be wholly 
transferable to other geographical locations or treatment settings. This study addresses the 
underrepresentation of the UK population in the existing literature. Future studies should seek 
to understand the situation of those who do not access healthcare.  
Theoretical Implications and Recommendations  
This study makes a unique contribution to the conceptual development of HCV 
treatment adherence among PWID. Compared to existing models of adherence, the data speaks 
to a different theoretical affiliation. The findings may linked to Attachment Theory (Bowlby, 
1979) and the evolutionary principles underlying compassion focused therapeutic approaches 
to lend further coherence and robustness to the findings. The ontological conjecture arising 
from this study is that humans are innately resilient, relational beings who have evolved to form 
bonds with others in a social context. When the correct conditions and contingencies of 
compassion and care are in place, the innate propensity to learn and grow can manifest in 
adaptive and engaged behaviour, including treatment adherence.  
Models such as the Information-Motivation-Behaviour Skills (IMB) Model of Adherence 
place information as the primary stimulus of behaviour change.  This grounded theory places 
the innate drive and capacity to obtain care and affiliation at the heart of human motivation. 
This conceptualisation is made more robust by a developmental understanding of adherence 
and PWID as a population, given that the prevalence of childhood and adult trauma is higher 
among heroin users and unhoused populations (Wang et al., 2010). Sensitivity to the bio-psycho-
social impact of abuse and neglect gives us a more complete understanding of the conditions 
that are more likely to be conducive to adherence behaviour in this group, beyond information 
giving. Human psychology is designed to respond to stimuli and integrate our perception into 
a narrative. When PWID are characterised as “chaotic”, there is a failure to appreciate what this 
may truly reflect: difficulty making sense of internal experience resulting in the absence of order, 




days of life and while this precipitates states of isolation and disconnection, reparative care-
giving experiences can facilitate new ways of relating to one’s emotional and physical needs.  
The grounded theory outlined here has utility in the field of HCV treatment adherence 
research as it can be used to develop quantitative studies of psychological variables. For example, 
the role of the care provider relationship in mediating or moderating adherence behaviour could 
be examined using standardised outcome measures. Additional qualitative research could seek 
to understand the perceptions of staff regarding engagement. Further research should seek to 
understand how the provision of good quality, sensitive, and compassionate care can be trained 
and preserved in this workforce.   
Clinical Implications and Recommendations 
This paper corresponds and responds to the conversation initiated by Harris and Rhodes 
(2016) using a qualitative approach to HCV treatment in the UK. Authors have expressed the 
“fundamental need for community based interventions” (Harris, M., Rhodes, 2016, p.86) in HCV 
treatment provision. This grounded theory concurs that community based, flexible, integrated 
harm reduction and social care services, alongside person-centred, continuous care are key to 
supporting sustained treatment engagement. For “treatment as prevention” to become a reality, 
individual and systemic factors need to be holistically addressed.  
Conclusion 
HCV treatment innovation has inspired declarations that the virus could be eliminated 
in the next 15 years (Watts, 2014). Regardless of how efficacious treatment becomes, the human 
condition is still subject to structural and psycho-social barriers (Harris et al., 2013). Alongside 
medication advances, policy and policy implementation need to progress in line with social 
justice values (Harris and Rhodes, 2016). Based on the current findings, it is recommended that 
HCV treatment providers prioritise two aspects of service provision: (1) optimising logistical and 
structural facilitators through community based treatment, and (2) protecting the interpersonal 
skills of staff as an essential human resource. Building relationships with vulnerable people takes 
time, energy and investment of emotional labour. This should be given due consideration in job 
planning and capacity forecasts for staff at the frontline of administering HCV treatment. 
Applied psychologists are well poised to provide enhanced understanding of HCV treatment 
adherence and working indirectly to support nursing staff in the service of optimising care for 
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Background: Staff turnover in substance misuse services has been established as a 
significant problem.  A lack of workforce stability negatively impacts both clinical care and 
organisational management, as continuity of care is key to engaging complex client groups. 
Turnover process models highlight employee morale, mobility and intention to leave as salient 
aspects of turnover. This systematic review provides a narrative synthesis of quantitative studies 
to ascertain factors associated with actual staff turnover in substance misuse services. 
Method: A search for peer reviewed journal articles from 1980 to 2016 was conducted 
using the following databases: PsychINFO, Medline, EMBASE and CINHAL. Studies were 
appraised according to eligibility and evaluated against 19 quality criteria. Appropriateness of 
design, methodological rigour, issues of bias and generalisability were assessed and reported on.  
 
 Results: Nine studies met inclusion criteria, reporting turnover among substance 
misuse counsellors, nurses and clinical supervisors. Factors that were associated with turnover 
included workforce characteristics (shorter tenure, staff having a history of substance misuse 
themselves), psycho-social variables (job satisfaction, relational skills) and organisational 
factors (job demand, prior turnover, and participation in management). Studies were considered 
to be of moderate methodological quality with limitations including: a lack of robust 
conceptualisation and measurement of constructs, poor integration and application of turnover 
process theory and a lack of generalisability to services outside the United States. 
Conclusions: Interventions to prevent turnover are needed, and are likely to be enhanced 
by improving social support and job satisfaction within the workforce. The destination of leavers 
should be considered in order to contextualise departure decisions within the broader economic 
climate.  
Keywords: Review, staff, nurses, counsellors, turnover, retention, substance misuse, 
organisation, job satisfaction.  





Scale of Turnover 
Turnover is consistently posited as a major problem in substance misuse services (Eby & 
Rothrauff-Laschober, 2012; Garner et al., 2012; Laschober, Turner, & Eby, 2013). Workers in this 
field are embedded in highly strained delivery systems, typified by small capacity and heavy 
caseloads (Eby, Ph, Burk, & Maher, 2010; McLellan, Carise, & Kleber, 2003; McNulty, Oser, 
Johnson, Knudsen, & Roman, 2007). A quality and performance report of a UK based National 
Health Service (NHS) Trust in London found that, over a one year period, 2015-2016,  addiction 
services had the highest staff turnover among 17 general, specialist mental health, and forensic 
services (Council of Governors, 2015). Annual rates of staff turnover have been recorded as high 
as 50%  in the United States (McLellan et al., 2003).  
Implications of Turnover 
There is an increasing pressure to adopt evidence based practice (EBP) within the field of 
mental health and substance misuse. The implementation of empirically supported 
interventions requires services to both train and retain competent staff on long-term basis 
(Garner et al., 2012). A lack of workforce stability subverts efforts to achieve programme level 
change within substance misuse, for example, the integration of mental and physical healthcare 
(Friedmann, Lemon, Durkin, & D’Aunno, 2003). Turnover represents a poor return-on-
investment regarding the resources spent on recruitment and training (Garner et al., 2012). The 
cost of nurse turnover has been estimated to be up to twice the salary of the nurse that left 
(McConnell, 1999). There may also be difficulties filling positions with suitably experienced and 
qualified staff (Gallon, Gabriel, & Knudsen, 2003). The efficiency of service provision is 
negatively affected, as capacity decreases, and demand remains the same, potentially leading to 
delays meeting statutory performance standards. 
Indirect costs include decreased morale among remaining employees and increased 
stress due to higher caseloads (Johnson & Roman, 2002; Knight, Broome, Simpson, & Flynn, 
2008). Turnover undermines stable, quality treatment provision and has been determined to 
have a harmful impact on client care in both private and public sector NHS settings (Ducharme, 
Knudsen, & Roman, 2008; Duffield, O’Brien-Pallas, Roche, & Catling-Paull, 2009). A UK-wide 
database of all suicides by people in contact with mental health services over a 12 month period, 
found that non-medical staff turnover (nurses, and other therapeutic staff), was significantly 
associated with suicide rates (Council of Governors, 2015). While the finding is not causal, and 
not specific to substance misuse services, the loss of a therapeutic relationship can have a 




been linked to better clinical outcomes within the substance misuse population, including 
longer treatment engagement and retention (Lamb, Greenlick, & McCarty, 1998).  
Models of Turnover 
A conceptual review of turnover process models concluded that the literature contains 
three components: employee morale, employment mobility, and intentions to leave/stay (Steel 
& Lounsbury, 2009). Mobility and intention to leave are proposed to be based on perceptions of 
the job market, the objective availability of alternative opportunities, and cognitive appraisals 
of the desirability of moving. The push–pull model (Jackofsky, 1984), extends the ease-of-
movement model (March & Simon, 1958), proposing that low performers are ‘‘pushed’’ out of 
the organization due to perceived threat of negative evaluation, and high performers are 
‘‘pulled’’ out of the organization due to greater job alternatives. Lastly, employee morale, which 
incorporates job satisfaction has also been posited as a core mechanism in turnover theory for 
many decades (Steel & Lounsbury, 2009). Authors have argued that departure decisions should 
be understood within the broader interpersonal context of the workplace (Knight, Landrum, 
Becan, & Flynn, 2012). Therefore, variables which capture collective support are being explored 
alongside individual-level predictors (Garner & Hunter, 2013). 
Current Review 
The evidence base has demonstrated a shift from the study of turnover intentions, to 
actual turnover (Garner & Hunter, 2013). A focus on turnover intention alone is limited, as staff 
may want to leave their job, but do not act on this for an indefinite period, due to mitigating 
factors (e.g. loss of a social network of co-workers, benefits such as health insurance, fear of 
financial instability) (Eby et al., 2010; Kammeyer-Mueller, Wanberg, Glomb, & Ahlburg, 2005). 
Meta-analytic research has shown that the correlation between turnover intention or 
withdrawal cognitions, and actual voluntary turnover is just 0.45, and recommends that the 
terms are not used interchangeably (Tett & Meyer, 1993). It is widely assumed that involuntary 
(initiated by employer) turnover is less welcome for organisations compared to voluntary 
(initiated by employee) turnover, as higher performing individuals choose to leave (Eby et al., 
2010; Laschober et al., 2013). Research also shows that when retention interventions are linked 
to the reasons why people leave their jobs, they tend to be more successful (Steel & Lounsbury, 
2009). Therefore, the most pragmatic way of understanding turnover is by identifying variables 
associated with actual voluntary turnover. Based on the need to address the problem outlined, 
the current study used a systematic review approach to answer two questions: (1) how is staff 
turnover operationalised in the field of substance misuse? (2) what factors are associated with 






The literature search was initially conducted in November 2016. To ascertain if a similar 
review had been conducted previously, the Cochrane Database of Abstracts of Reviews of 
Effective Practice and Organisation of Care was searched. This scoping search generated only 
one article loosely linked to the current topic, a systematic review of controlled studies assessing 
the effect of exit interviews to reduce staff turnover in healthcare (Webster & Flint, 2014). 
Searches were subsequently undertaken using PsychINFO (1987-2016), EMBASE (1980-2016), 
MEDLINE (1946-2016) and CINHAL (1937-2016) electronic databases, covering biomedical and 
psychological literature, including European and American peer reviewed journals. A time 
parameter was set from January 1980 to November 2016 to gather recent evidence in line with 
the aim of the review. To formulate the search string, terminology and common key words were 
adopted from other systematic reviews in the field (e.g. Van Boekel, Brouwers, Van Weeghel, & 
Garretsen, 2013). The population of interest was substance misuse staff, representing clinical 
personnel in general, and specific professions such as nursing and counselling (“staff” OR 
“employ*” OR “personnel” OR “team” OR “nurs*” OR “cousell*” OR “psych*” OR “social work*”). 
The second group of search terms described workplace settings, services for the substance 
misuse client group (“substance *use” OR “substance abuse” OR “substance use disorder” OR 
“alcohol addiction” OR “drug addiction” OR “opioid-dependent” OR “drug detox” OR “drug 
rehab*” OR “methadone maintenance” OR “harm reduction”). The last group of search terms 
comprised the outcome of actual staff turnover (“turnover” OR “retention”). A manual search of 
reference lists from the included articles was also used. To minimise publication bias, primary 
authors from included studies were approached. One was not contactable and of those who 
responded, no additional unpublished research was suggested.  Searches were limited to studies 
published in English, as translation was not feasible. 
Study Selection 
Fig. 1 shows a flowchart of the selection process. In the first selection phase, titles of all 
articles were screened based on three conditions within the domains of title, abstract and 
keywords: (1) focus on substance misuse services, (2) actual staff turnover was the subject of the 
study and (3) factors associated with actual turnover were studied quantitatively.  Any article 
that fulfilled at least two of these parameters or were ambiguous in one aspect, proceeded to the 








• Studies published in English, using a quantitative, or mixed method design 
(observational, cohort/cross-sectional, longitudinal). 
• Subjects of the study are clinical professionals (nurses, counsellors, supervising 
clinicians) working in substance misuse services (alcohol or illicit drug 
treatment/detox, methadone maintenance, harm reduction). 
• Studies primarily focussed on factors associated with actual staff turnover in 
substance misuse. 
• Studies focussed on generating quantifiable empirical data to compute the 
strength and/or association of factors related to staff turnover in substance misuse.  
Exclusion criteria  
• Studies that are purely descriptive or theoretical. 
• Studies using only qualitative methods, individual case studies or treatment 
studies.  
• Studies of turnover in services that may or may not serve a substance misuse 
population (general adult mental health or forensic services) or unspecified. 
• Studies focussing on turnover intention, burnout, emotional exhaustion or related 
constructs as outcomes, but do not consider actual turnover. 
• Subjects of the study are administrative, or non-clinical staff, or clients. 
 
Table 1: Inclusion/Exclusion Criteria 
 
Data Extraction and Synthesis 
Data was extracted on each study’s aims and hypotheses, setting and characteristics of 
study population, sample size, study design, outcomes and measurement, and main results or 
conclusions (Table 4). Initially, the data extraction protocol was pilot-tested with two randomly 
selected studies, and refined accordingly. The first author (C.M.B.) extracted the data from 
selected studies and implemented the quality assessment tool. Reporting followed 
internationally accepted guidelines for producing systematic reviews as outlined by the Centre 
for Reviews and Dissemination (CRD), The University of York. 
Quality Assessment 
The current review used a checklist of 19 item quality criteria identified a priori to assess 
studies. In line with CRD recommendations quality criteria that are relevant and specific the 
current research question were employed. Issues of design, operationalisation of variables, 
reliability and validity of measures, representativeness and generalisability were considered 
(www.york.ac.uk/inst/crd/), the themes of which are summarised in Table 2. Each paper was 
rated on each item in accordance with Scottish Intercollegiate Guidance Network ratings of 
methodological quality. A 2 or 3 points based scale, depending on the relative importance of the 
specific item (for full description see Appendix VI). Outcome ratings were allocated as follows: 
“well covered” (3 points), “adequately covered” (2 points), “poorly addressed” (1 point), “not 




quality assessment was conducted independently by a second reviewer (C.G) on a sample of 
studies (N=4; 44%). There was exact agreement on 78% (59/76) quality ratings, with a small 
amount of variance, with a difference of 2 points on 3% of items (3/76). Discrepancies in quality 
ratings were resolved via discussion and reviewing the original articles until a consensus was 
reached. A narrative synthesis of findings was also developed. The terms and definitions used in 
the original studies were used.  
 
 Rationale and objectives: how clearly is the purpose of the study stated, including 
research question(s) and/or hypotheses? 
 Design: how well does the methodology address the research question(s), how clearly 
is the study setting (service provision or structure of the substance misuse facility) and 
recruitment described? 
 Variables: how clearly are constructs operationalised, how is the outcome variable (staff 
turnover) calculated? 
 Reliability and validity of measures: how clearly is the data source described and is data 
cross-referenced if appropriate (e.g. if gathered retrospectively from an internal 
database), how reliable and valid are the outcome measures used?  
 Descriptive data: how clearly is the sample described (e.g. tenure, recovery status of 
staff), is the sample representative of the population being studied based on their 
characteristics and response rate? 
 Outcome data: how clear and appropriate are the statistical analysis used, is a power 
calculation reported?  
 Treatment of confounds: have confounding variables (e.g. staff tenure) been controlled 
for? 
 Completeness of data: how clearly have attrition and missing data been reported on, 
accounted for and handled to minimise bias? 
 Interpretation and generalisability: how clear and cautious are the results in the context 
of limitations and existing evidence, does the data justify the conclusions drawn? 
 Funding: are funding sources acknowledged, alongside their role if applicable, are 
ethical issues stated and addressed if applicable?  
 
Table 2: Summary of Quality Indicators  
Results 
Search Results 
The database search yielded 507 potentially relevant citations. Following de-duplication (n=46), 
a further 430 articles were removed after the first selection phase of screening the title and 
abstract. Therefore, 28 citations proceeded to the next stage where full text articles were 
examined leading to the final inclusion of 9 studies which met full inclusion criteria. This 
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 Records identified from CINHAL 
(N = 137) 
Total records identified from databases 
(N = 507) 
Records after de-duplication (N = 461) 
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(N = 46) 
Full-text articles assessed for 
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Studies included in narrative synthesis 
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-Theoretical study (N=3) 
-Not quantitative (N=2) 
-Not specific to substance 
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-Concerning organisational 
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-Concerning other outcome 
variables not specific to 
review question (e.g. 
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Characteristics of Included Studies 
Data was collected from a large number of substance misuse treatment programmes 
ranging from a sample of 25 outpatient community based substance abuse treatment facilities 
(Knight et al., 2012) to 217 private-sector alcohol and drug abuse treatment centres the majority 
of which were hospital based (McNulty et al., 2007). Seven were adult services, and two were 
adolescent facilities (Garner et al., 2012; 2013). Most programmes were situated within 
community based outpatient facilities. One study specified that staff had inpatient duties 
(Laschober et al., 2013). Descriptions of setting (e.g. organisation structure and service 
provision), location and recruitment method (e.g. periods of recruitment, follow-up, and data 
collection) were generally clear and appropriate across studies.  
Seven studies looked at substance misuse counsellor turnover, one focussed specifically 
on nurses (Knudsen et al., 2011) and one on counsellor supervisor turnover (Knight, Broome, 
Edwards, & Flynn, 2011). Just one study stated explicitly that counsellors had direct therapeutic 
contact with clients individually or in a group (Laschober et al., 2013). In the sampled studies, 
the majority of staff were middle-aged Caucasian females, with an average age ranging from 35-
47 years old. The majority of staff recruited across studies were highly educated to Master’s 
degree (>40% across studies) or at least Bachelor’s degree level, and had a per annum salary of 
between $30-34,000 (conversion is equivalent to experienced drug and alcohol workers in the 
UK). Four papers described that that the majority of staff sampled had 5+ years substance misuse 
counselling experience (Knight et al., 2011; 2012). Regarding tenure, only one study described 
that 42% of counsellors who had left their organisation had been in post for <1 year at the time 
of departure (Knight et al., 2012). The frequency of counsellors described as “in recovery” from 
personal substance dependence, ranged widely including rates of 5% (Garner & Hunter, 2013), 
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Task performance - 20-
item scale* 
Relational performance 
– Eby et al., (2008) 7-
item scale.  
Organisational 
citizenship behaviours - 
Williams and 
Anderson's (1991) 7-item 
scale. 
 
23% No difference in task performance 
between voluntary leavers and those 
who stay. Both voluntarily and 
involuntarily leavers were lower in 
relational performance than stayers. 
Both higher and lower levels of 
individual organisational citizenship 
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(Heneman & Schwab, 
1985) 
Job Involvement Scale 
(Reeve & Smith, 2001) 
Turnover intentions – 
scale* 
23%^ Within the construct of work 
attitude, job satisfaction, turnover 
intention and job involvement were 
found to be significantly associated 
with turnover. More positive 
psychological climate was predictive 
of more positive work attitude 
(𝛽=0.87 ρ<.001). Work attitude fully 
mediated the relationship between 
psychological climate and turnover 
(hOR=0.95; ρ=.95) 
Together psychological climate and 
work attitudes explained 16% of the 







(programme needs, staff 
attitudes, organisational 
















6, 9, 12 
Survey of Organisational 
Functioning (SOF) – 
(Broome, Knight, 
Edward, & Flynn, 2009) 
31% The odds of transitioning to the not 
employed/not EBP-competent status, 
were significantly higher for males 
(OR=2.94) and greater perceived 
programme needs (OR=1.19), and 




practices) as predictors 
of competence and 
turnover status at 3 time 
points post-training in 
an evidenced based 
model. 
 
significantly lower for staff reporting 
higher levels of mission (OR=0.86), 
satisfaction (OR = 0.88), director 
leadership (OR=0.90), and collective 
responsibility (OR=0.90). 
Programme needs was the only 
predictor that was significantly 
linked to transition to not 
employed/not EBP-competent at 12 
months (ρ =.018 <.05). 
 

















role performance) as 
predictors of voluntary 













24, 36, 48 
 
Distributive justice - 
Moorman's (1991) four-
item scale. 
Procedural justice - 
Niehoff and Moorman's 
(1993) six-item scale. 
Perceived organizational 
support - Eisenberger, 
Cummings, Armeli, and 
Lynch's (1997) eight-
item scale.  
Job satisfaction - Smith's 
(1976) six-item scale 
Relationship quality - 
Allen and Eby's (2003) 4-
item scale. 
Supervisors' extra-role 
behaviours - Williams 
and Anderson's (1991) 7-
item scale. 
Supervisors' in-role 






Counsellors with higher perceived 
procedural justice, distributive 
justice and job satisfaction were 
14.7%, 18.2% and 22.8% less likely to 
leave voluntarily over the next 3 years 
than other counsellors respectively.  
Counsellors with more favourable 
perceptions of the organizational 
environment are between 13.8% and 
22.8% less likely to turnover. None of 




































Programme needs x change 
orientation interaction (t=−3.03, 
ρ<.01) was a significant predictor of 
voluntary turnover, as were tenure 
(t=−1.90, ρ<.05), satisfaction (t= 
−2.23, ρ<.05). 
Staff who left voluntarily reported 
lower change orientation, (t= 2.34, 
ρ<.05), and lower satisfaction, (t=3.13, 















criminal justice and 
dually diagnosed clients, 
caseload no. and no. 


















Survey of Structure and 
Operations (SSO) - 




33%  33% of programmes reported change 
in supervisor within 12 months.  
Programmes affiliated with a parent 
organisation had 4 times the turnover 
of those not affiliated with a larger 
body (OR=4.45).  
Parent affiliation and satisfaction 
were significant predictors after 
controlling for structure measures 
and director leadership (p<.05). 
Satisfaction is a marginally significant 
predictor of turnover in programmes 










characteristics relate to 
nurse turnover and 




















location, for profit, 
accreditation status, 




programme operations.  
 
15%^^ A vacant nursing position took 2 
months to fill (M=74.4 days, 
S.D=61.6). 
Nurse turnover was positively 
associated with offering residential 
treatment and reduced operations 
within the last two years (ρ <.05) and 
negatively associated with adolescent 
only treatment services (ρ <.05) and 










investigated reasons for 

































exploratory;  structured 
interviews with a  subset 





Most common reason for counsellor 
& supervisor turnover was a new job 
opportunity (27.3%, 29.5% 
respectively). 
Personal reasons for voluntary 
counsellor and supervisor turnover 
included: relocation, personal health, 
return to school and retirement. 36% 
of counsellors who left the 














based, for profit, 





recovery status) and 
client-counsellor 
relations (clients in 
relapse, court-mandated 
clients, Medicaid clients 
and managed care 
referrals) as predictors 
of turnover. 
 
Total N staff 
not stated.  
57%  















management - Niehoff 
and Moorman's (1993) 
six-item scale. 
Organisational 
commitment - 4-item 
scale developed for the 
study. 






Prior turnover is positively related to 
subsequent turnover until the prior 
turnover rate reaches about 48%. 
34% of the variance in turnover rates, 
was explained by a model including 
indicators of centre and workforce 
characteristics. 
Percent of counsellors in recovery has 
the strongest effect on turnover (β = 
.301), percent certified (β = −.239), 
centre capacity (β =.217), prior 
turnover (.230, −.170), percent 
minority (β = −.213), profit status 
(.192), percent managed care referrals 
(β = −.168), percent female (β =.152), 
and organizational commitment (β = 
−.153). 
 
Table 3: Summary of Study Characteristics  




Factors Associated with Turnover 
Workforce Characteristics 
Two studies recorded personal reasons for voluntary turnover including retirement, 
relocation, return to education, family concerns and changing career (Eby et al., 2010; Knight et 
al., 2012). Eby et al. (2010) reported that “new job/other opportunity” was the most common self-
reported reason for both counsellor and clinical supervisor turnover.  Regarding tenure in an 
organisation, those who have been employed for fewer years are more likely to turnover 
voluntarily (t=−1.98, ρ<.05 (Knight et al., 2012). Counsellor certification status, years of 
experience in substance misuse counselling, or salary were not found to be linked to voluntary 
turnover (Garner & Hunter, 2013; Laschober et al., 2013). Counsellors with their own previous 
history of substance misuse, who were now in recovery (‘recovery status’) were more likely to 
leave their jobs. Counsellor recovery status was the strongest individual predictor of turnover 
across different regression models (McNulty et al., 2007).  
Performance  
Helping behaviour towards colleagues had a curvilinear influence on the relationship 
between job performance and voluntary turnover (Laschober et al., 2013).  Laschober et al. (2013) 
found that counsellors who were rated lower by their supervisors on their relational 
performance (e.g. being considerate of, and responsive to colleagues) were more likely to 
turnover voluntarily compared to their colleagues that remained employed, where an Odds 
Ratio (OR) of >1 indicates a negative relationship (OR=0.69, ρ<0.01). Lower task performance 
was significantly related to involuntary, but not voluntary staff turnover. Regarding strategies 
to upskill the workforce, 31% of staff who completed in house training in evidence based practice 
were not employed one year after the event. However, this study did not differentiate between 
voluntary and involuntary turnover, and did not provide a comparison of turnover rates among 
staff who did not receive training (Garner et al., 2012).  
Psycho-social variables 
Job Satisfaction 
Job satisfaction was the most consistent factor associated with staff turnover, and was 
found to be a significant predictor in four studies where it was included in the final multi-variate 
analysis (Eby & Rothrauff-Laschober, 2012; Garner et al., 2012; Knight et al., 2011, 2012).  
Counsellors with higher job satisfaction were 22.8% less likely to voluntarily leave the 
organisation within 3 years (β=-0.26, ρ<.01) when race, gender, tenure in the organisation and 
certification level was controlled for (Eby & Rothrauff-Laschober, 2012). In another study, after 




affiliation, service approach), lower job satisfaction was a significant predictor of turnover (t=-
2.23 ρ<.05) (Knight et al., 2012).  
Work Attitude 
Using a mediational model of analysis, Garner and Hunter (2013) concluded that work 
attitude (including job, pay and benefit satisfaction, intentions to quit and job involvement) 
fully mediated the relationship between “psychological climate” and turnover. The sample was 
conservative (N=95) and no power calculation was described.  
Organisational factors 
A model combining counsellor-management relations, centre characteristics, and 
workforce composition explained 32% of the variance in voluntary counsellor turnover 
(McNulty et al., 2007). Workforce composition (i.e. frequency of certified counsellors, 
counsellors in recovery) and centre characteristics (i.e. greater capacity, prior turnover and for-
profit status) explained the effects of the latter variables on turnover (McNulty & Oser, 2007). 
Higher participatory management and organisational commitment were related to lower 
voluntary turnover (McNulty et al., 2007). Similarly, higher perceived organisational support, 
but not relationship quality with a clinical supervisor, protects against staff turnover; 
counsellors who felt greater levels of support were 13.8% less likely to leave their job over the 
next 3 years  (β=-0.15, ρ<.05) (Eby & Rothrauff-Laschober, 2012).   
Job demands  
Using a subset of a larger sample, Knight et al. (2012) reported that the likelihood of staff 
turnover was higher for those who perceived higher programme needs (or job demands), when 
organisational change orientation was low. The latter variable communicates the willingness 
and flexibility of an organisation to adjust and adapt to demands. The association remained 
significant after controlling for programme characteristics, staff demographics and ratings of 
stress, burnout and satisfaction. Job demands was the only variable that remained a significant 
predictor of staff turnover at 6, 9, and 12 month follow-up, where higher demands precipitated 
greater turnover (OR=1.16, ρ<0.05) (Garner et al., 2012). McNulty et al. (2007) assessed features 
of the client group, including relapsing clients, court-mandated, and low-income clients. Only 
managed care referrals were significantly negatively associated with voluntary turnover (β=-
0.168 ρ<.01). The specific needs of these cases were not described, however it is stated that these 
clients are generally employed, indicating a greater degree of occupational functioning. 
Residential treatment (β=0.508, ρ<.05) and services that had ‘reduced operations’ in the 
previous 2 years (β=0.412, ρ<.05) (Knudsen et al., 2011) were both positively associated with 




Methodological Characteristics and Quality of Included Studies 
Table 5 provides ratings for each of the studies on the 19 quality criteria. This scale does not 
provide a basis for exact comparison, but does act as an indication of relative methodological 
strengths and weaknesses. The systematic rating of studies suggests that Laschober et al. (2013) 
and Knight et al. (2012) were the methodologically strongest studies with the greatest number 
of adequately and well covered criteria. These two studies clearly addressed the relationship 
between variables, using an appropriate design and cross-referenced data source. Overall, the 
quality of reviewed studies was reasonable, meaning that at least half of criteria were well or 
adequately covered. Limitations regarding the reliability of measures and issues of 
representativeness may have modestly affected the findings or conclusions. 
Design 
Most studies used exploratory, observational designs. One of the methodologically 
strongest studies (Laschober et al., 2013) uniquely used a design comparing groups of those who 
stayed and those who left voluntarily and involuntarily. Garner et al. (2012) also compared 
groups but did not distinguish voluntary from involuntary leavers. Six were original studies and 
3 studies reported the secondary analyses of a larger dataset. Subsequent studies examined a 
different research question using the same dataset (Eby et al., 2010, 2012; Garner et al., 2012, 2013) 
or reported counsellor and supervisor turnover separately (Knight et al., 2011, 2012). Studies 
suffered from a lack of robust construct reliability and validity, as outcome variables were at 
times poorly described and vague (e.g. “psychological climate”, or “individual organisational 
citizenship behaviour” or “reduced operations”).  The measures used across studies varied, but 
there were some commonalities. Three studies (Garner et al., 2012; Knight et al., 2011, 2012) used 
the Survey of Organizational Functioning (SOF), which has 129 items. As this measure was used 
in a number of studies, the psychometric properties were reviewed independently. The SOF is 
an expanded version of the Organizational Readiness for Change (ORC) instrument (Lehman, 
Greener, & Simpson, 2002), with the addition of a job attitude scale measuring perceptions of 
leadership, job satisfaction, and burnout (Broome, Knight, Edward, & Flynn, 2009). The 
development of the original measure, the ORC, was not supported by a confirmatory factor 
analysis (CFA) and five of the eighteen scales demonstrated questionable internal consistency. 
No validation studies for the SOF have been published to date. The psychometric properties of 
this tool make findings based on the ORC, and the revised SOF measure highly tentative. Three 
studies developed their own scales for the purpose of measuring task performance (Laschober 
et al., 2013), in-role job performance (Eby & Rothrauff-Laschober, 2012), psychological climate 




validity was demonstrated with an acceptable alpha co-efficient (α<0.70), the reliability of 
measures was not determined by CFA (DeVillis, 2012).  
Representativeness  
All studies were affiliated with large-scale evaluations of substance treatment facilities 
across the United States, including a combination of private and public facilities. Three studies 
only included organisations that were affiliated with the National Institute on Drug Abuse’s 
Clinical Trials Network (Eby et al., 2010; Eby & Rothrauff-Laschober, 2012; Knudsen et al., 2011). 
While this does not constitute a random sample, one study (Eby et al., 2010) compared the 
characteristics of their sample to two nationally representative samples of substance misuse 
treatment facilities (see Ducharme, Knudsen, & Roman, 2008) and found that they were similar 
in terms of representations of age, gender, education level and certification. Other indications 
of representativeness (quality criteria: 11, 14, 15) were generally poorly, or not addressed by 
studies. The studies that were rated higher on methodological quality reported response rate, 
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(2012) 
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Knight et al., 
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Eby et al., (2010) 
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McNulty et al., 
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Table 5: Ratings of Study Quality 
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Statistical methods, 9. Descriptive data, 10. Power of sample size, 11. Representativeness, 12. Outcome data, 13. Confounds, 14. Attrition, 15. 
Missing data, 16. Key results, 17. Limitations, 18. Interpretation & generalisability, 19. Funding & Acknowledgements 





Operationalisation of the Outcome Variable 
The measurement of turnover was consistent but not wholly uniform across studies. Five 
studies used a standard formula for establishing turnover, which was operationalised as a 
percentage (the total number of individual staff that had left the organisation, during a specified 
period of time, divided by the total number of individual staff employed at a baseline time 
point). Two studies reported the actual, raw number of counsellors (Knight et al., 2012) and 
supervisors (Knight et al., 2011) who had left, rather than expressing turnover as a rate. Two 
studies calculated a less valid measure of turnover, in the form of an average annualised rate 
(Knudsen et al., 2011; McNulty et al., 2007). McNulty et al. (2007) based the turnover rate on a 
different sample (obtained 2000-2001) to the sample used to generate predictor data (obtained 
1997-1998). Two studies did not distinguish between voluntary (initiated by staff member) and 
involuntary turnover (contract terminated by the organisation/employer) (Garner et al., 2012; 
Knight et al., 2011), indicating a significant limitation to comparison with other studies as the 
factors precipitating involuntary turnover are typically different (e.g. dismissal for misconduct).  
Source of Data 
Source of data was consistent across studies, where employment status of individual 
employees was commonly based on information provided by directors, managers, clinical 
supervisors or using HR/administrative records (exit interview contained in the employees 
personnel file) (e.g. Eby, Ph, Burk, & Maher, 2010). This method has been critiqued for accuracy, 
depending on the quality of internal record keeping (Eby et al., 2010). Retrospective or self-
report data may also be subject to bias where attributions for turnover may be influenced by 
social desirability or legal diplomacy (Eby et al., 2010). In one study (Laschober et al., 2013) data 
on job performance was compiled from the evaluation of supervisors of counsellors they worked 
with. which may have influenced estimates of job performance. Moreover, supervisors 
completed questionnaires for a range of between 1-9 counsellors, indicating a risk of survey 
fatigue. Efforts have been made to check and validate data collected from organisation 
management by triangulating data collection. Studies that scored more highly on the quality 
criteria (see Table 5) cross-referenced their findings by conducting exit interviews with people 
who had left the organisation (e.g. Eby, Ph, Burk, & Maher, 2010; Laschober, Turner, & Eby, 
2013). All studies provided financial reimbursement to organisations to compensate for the time 
required to provide data, potentially enhancing the accuracy of the data collected. 
Discussion 
Staff turnover in substance misuse is an extensive and concerning phenomenon. In the 




workforce had left their current employment over a 12 month period. It is difficult to remain in 
a field that is characterised by poor pay, low status and emotionally exhausting work on a long-
term basis (Eby & Rothrauff-Laschober, 2012). Findings show that factors other than salary or 
clinical complexity were more robust precipitants of turnover. The specific factors that were 
associated with turnover included workforce characteristics (shorter tenure, recovery status), 
psycho-social variables (job satisfaction, relational performance) and organisational factors (job 
demand, prior turnover, and participation in management). The dynamic interplay between the 
organisational and individual context forms a thematic thread throughout the studies reviewed. 
Findings should be interpreted within the methodological limitations of existing research. 
Factors Associated with Turnover 
Findings are consistent with meta-analytic research in organisational psychology which 
posits job satisfaction as one of the best proximal precursors of staff turnover (Griffeth, Hom, & 
Gaertner, 2000; Steel & Lounsbury, 2009). Job satisfaction has been conceptualised as a function 
of the employee unit; an organisational attribute, rather than a quality of an individual (McNulty 
et al., 2007). McNulty et al. (2007) have argued for the development of multilevel models that 
situate turnover behaviour in a social context, which recognises how the individual behaviour 
is embedded within, and potentially cued by systemic triggers. Organisational dynamics and 
individual decision-making influence each other synergistically (Knight et al., 2011). Having an 
effective clinical supervisor was not enough to offset turnover among counsellors indicating, 
that collective relationships rather than specific dyads, may be more influential. Similarly, even 
when employees are committed to the organisation and feel engaged with management, prior 
turnover explained the effect of counsellor-management relations on turnover (McNulty et al., 
2007).  
Both lower and higher levels of relational performance were related to voluntary turnover 
(Laschober et al., 2013). Employees demonstrating higher levels of helping behaviour toward 
colleagues may precipitate additional interpersonal burden, increasing the risk of burnout 
(Laschober et al., 2013). Lower levels of support for others was attributed to a lack of person-
environment fit. Authors hypothesise that in caring professions, “going the extra mile” to help 
colleagues is an implicit expectation among peers. The absence of this behaviour may indicate 
interpersonal difficulties or unsupportive work relationships, which may feed into voluntary 
turnover. Task performance was not significantly higher among those who left the organisation, 
disproving theoretical supposition that higher performers are “pulled” into better jobs as 
suggested by Jackofsky’s push-pull model (1984). 
Structural features of a service, including greater centre capacity and affiliation with a 




population. Downsizing in residential settings may lead to changes in staff work patterns, 
including more anti-social shifts, or reduced hours, potentially making employment financially 
unviable for some employees (Knudsen et al., 2011). Indicators of client complexity were 
generally not found to be associated with turnover (McNulty et al., 2007). This finding may be 
considered counter-intuitive as injecting drug users can demonstrate high risk, challenging 
behaviour which is linked to higher stress and lower job satisfaction in staff (von Hippel, Brener, 
& von Hippel, 2008). This supports the conclusion that decisions to leave were based factors 
outwith features of the client population (Eby et al., 2010). 
Strengths and Limitations of Review 
Publication bias was managed by corresponding with authors of all included studies to 
included unpublished literature. Subjective bias in the rating of methodological quality was 
minimised by establishing high level of inter-rater reliability between independent reviewers. 
The review was limited to studies published in English. Some relevant databases were not 
included and a set combination of search terms were employed. To minimise heterogeneity of 
studies, strict inclusion and exclusion criteria were applied, such as limiting included studies to 
those that reported actual turnover rather than turnover intention, though this demarcation 
affords greater specificity and pragmatism to the review findings. Certain study designs (e.g. 
qualitative work, treatment trials) were also excluded. Such criteria may present a limitation to 
the scope of the search strategy by potentially excluding relevant studies.  
Clinical Implications 
Empirical evidence supporting the importance of job satisfaction, offers direction in 
developing interventions to promote workforce retention in substance misuse (Knudsen et al., 
2011). Job satisfaction can be understood as, “feeling genuinely cared for, valued and supported 
by the organization … by meeting needs for approval, esteem, and community at work” 
(Eisenberger, Huntington, Hutchison, & Sowa, 1986). Counsellors are less likely to leave a work 
setting with high job demands, if they feel the organisation as a whole is orientated towards 
change (Knight et al., 2012). A culture of openness and flexibility may therefore protect against 
staff turnover by promoting prosocial engagement, belonging and connectedness thereby 
enhancing overall job satisfaction. These values should be articulated in policy, as a basis for 
communication and conflict resolution protocols and integrated into the induction of new 
employees (Knight et al., 2012). An intervention that involved acceptance skills and public 
declaration of values among staff has been found to have a superior positive impact on burnout 
among substance misuse counsellors, compared to multicultural training, at 3 month follow up 
(Hayes et al., 2004). Other suggestions for improving job satisfaction include greater 




autonomy in daily clinical work, and support for professional development through the 
provision of frequent, and positive feedback and recognition of performance (Eby & Rothrauff-
Laschober, 2012). In order to maximise the long-term, sustained implementation of evidence 
based practice, interventions that support collective job satisfaction should be considered 
alongside changes to practice (Garner et al., 2012). To counteract the potentially negative impact 
of job demands on counsellors working in substance misuse, Knight et al. (2012) advocate for 
the allocation of resources to promote social support and affirm a culture of connection and co-
operation. Eby et al. (2010) advocate team building workshops to enhance relationships. 
Leadership effectiveness should also be monitored at a managerial level, but rather than 
prioritising clinical and/or administrative competence, supervisors should be rewarded for their 
interpersonal skill (Eby et al., 2010). Staff may voluntarily leave the workplace due to 
degenerative physical illness, trainee counsellors rotating work placements, and family 
obligations such as parental leave (Eby et al., 2010), the latter of which may be particularly 
relevant to a largely middle-aged female substance misuse workforce. An organisational policy 
or protocol that includes exit interviews would help to clarify salient circumstantial factors that 
lead to turnover (Webster & Flint, 2014). 
Theoretical Recommendations 
There are several ways in which the study of staff turnover in substance misuse services 
can progress:  
Measurement and Design 
Existing evidence has scarcely moved beyond correlational models of analysis which do 
not demonstrate causality between variables. The poor quality of measures (e.g. the SOF) used 
to assess factors associated with staff turnover is also a drawback. Future studies should examine 
psychological variables such as stress, burnout and job satisfaction using standardised, valid and 
reliable measures to increase methodological quality, e.g. the Maslach Burnout Inventory 
(Maslach & Jackson, 1981). 
Application of Theory 
Ease of mobility and turnover intention are two constructs common in turnover process 
models (Steel and Lounsbury, 2009). The inclusion of studies that examined actual staff 
turnover is a methodological strength of this review, surprisingly however, the studies reviewed 
did not explicitly investigate the relationship between turnover intention and actual turnover. 
Empirical studies in this field would be more robust if they were more closely linked to turnover 
theory. The objective availability and subjective perception of alternative opportunities within 




portion of staff who voluntarily turnover, ease of transition to other facilities via intra-
organisational transfer, or availability of alternative work will have been influential (Garner and 
Hunter, 2013). Increased focus on the destination of leavers would address this gap. Exploration 
of external factors and personal circumstance which lead to turnover would support the 
development of the field (Steel & Lounsbury, 2009).   
Directions for Future Research 
Geo-centrism currently limits the generalisability of findings due to differences in how 
substance misuse services are organised and funded in different countries. Turnover research 
based in healthcare systems that are publicly funded would enrich the field. Secondly, three 
authors, Dr. Bryan Garner, Dr. Lillian Eby and Dr. Danica Knight dominate the field of staff 
turnover in substance misuse. While an evidence base that is produced by a small number of 
highly specialised researchers can potentially increase the risk of bias, this niche expertise can 
also promote quality through increased liaison and shared practice. Future studies should 
subscribe to a standard format to report on the setting and sample. A complete description 
would include recovery status, levels of education, professional grouping, salary, tenure, 
professional certification/accreditation, nature of employment contract, and years of specialised 
experience. Response rate, missing data and attrition should also be reported uniformly. This 
would facilitate the equitable comparison and synthesis of data. 
Conclusion 
This systematic review shows that the current evidence base for factors associated with 
staff turnover is developing but is not yet robust. Rates of counsellors, nurses and clinical 
supervisors that turnover within a year show that turnover is a significant problem that needs 
to be addressed. The studies reviewed were generally of reasonable quality, however limitations 
were evident in the operationalisation and measurement of variables. All studies reviewed were 
based in the US indicated that research should be conducted in different geographical and 
organisational contexts. The findings that were synthesised, highlighted that job satisfaction is 
likely to be a predictor of actual turnover in substance misuse services, and should be examined 
further. The social and interpersonal context of staff and good quality of relational support may 
be an area of consideration for managers and should be an area of advocacy in organisational 
policies.  
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needed.  





1) Please provide a brief critical review of relevant literature, which should 
clearly demonstrate the rationale and scientific justification for the research.  
(Relevant to IRAS A12) (Guideline 1000 to 1500)  
 
Scope of the Problem 
Chronic hepatitis C virus (HCV) is a global public health concern, affecting over 130 million 
people worldwide (World Health Organisation, 2004). In 2004, the Scottish Government 
recognised that “hepatitis C is one of the most serious and significant public health risks of our 
generation” (Chisholm, 2004). An estimated 39,000 people are currently living in Scotland with 
HCV (Shepard, Finelli, & Alter, 2005). Regarding transmission, one prevalence study estimated 
that 90% of those infected acquired their virus through injecting drug use behaviour by sharing 
needles/syringes and other injecting paraphernalia (Roy et al., 2007). The majority of new 
infections occur within the intravenous drug using population (Health Protection Scotland, 
2008). The health and economic toll of HCV is substantial; Vietri and colleagues (Vietri, 
Prajapati, & El Khoury, 2013) have sought to quantify this cost across five European countries. 
The research concluded that there is a significant human and financial loss associated with HCV 
in terms of worker absenteeism, presenteeism (impairment while at work), and general 
impairment in occupational functioning in those affected. Approximately one fifth of cases go 
on to develop cirrhosis and liver cancer (Shepard, Finelli, & Alter, 2005). UK national data shows 
that hospital admission rates and mortality from HCV-related liver conditions are 
underestimated (Palmateer, Hutchinson, McLeod, Codere, & Goldberg, 2007) and are 
continuing to rise (Public Health England, 2014). These findings suggest that HCV will become 
a significant and pervasive societal burden over the next 20 years unless more individuals 
successfully undergo antiviral treatment (Patruni & Nolte, 2013). Having outlined the scope of 
the problem globally and locally, this brief review will discuss treatment for HCV, outline 
treatment adherence interventions and biopsychosocial factors, identify an important 
knowledge gap in this area and finally propose a study to address the limitations of current 
knowledge and research.   
 
Treatment and Adherence 
There is significant potential for savings within the NHS and a substantial increase in economic 
output and productivity if more people with HCV are successfully treated. Estimates predict 
that quadrupling treatment rates would halt the rise in projected prevalence of HCV infection 
in the UK (Patruni & Nolte, 2013). Scottish Government HCV Action Plan (The Scottish 
Government, 2008) is a major initiative to deal with the epidemic of HCV on a national scale; it 




decreasing number of people experiencing serious complications such as liver failure, for whom 
treatment costs are substantially higher. HCV can be effectively cured using ‘combination anti-
viral therapy’, potentially reducing liver-related morbidity and mortality (Weiss, Bräu, Stivala, 
Swan, & Fishbein, 2009). While the cost of a course of antiviral therapy is, on average, £8,000, 
treatment is still deemed highly cost effective by both the National Institute for Health and 
Clinical Excellence (NICE, 2013) and Quality Improvement Scotland (SIGN, 2006). Effective 
treatment raises the possibility of reducing prevalence by using anti-viral therapy as prevention 
(Martin et al., 2011) and specifically targeting active infected drug users who are the main source 
of new infections (Roy et al., 2007). Despite this opportunity, under current treatment patterns, 
overall prevalence of Hepatitis C infection in the UK is predicted to rise by a third by 2035 
(Patruni and Nolte, 2013). This indicates that while effective treatment for HCV is available, 
outcomes may be hindered by health behaviour.  
 
Adherence to treatment is crucial to the success of any prescribed medication regime and is 
required for patients to attain a sustained virological response to HCV (Grebely et al., 2009; 
McHutchison et al., 2002; Mulhall & Younossi, 2005). However, a large proportion of patients 
(up to 50%) have difficulty in taking the recommended 80% of doses for greater than 80% of the 
recommended treatment duration, thereby impeding positive treatment outcomes (e.g. Grebely 
et al., 2011; McHutchison et al., 2002; Manos, Ho, Murphy, & Shvachko, 2013). Non-adherence is 
often related to undesirable side effects (e.g. Treloar, Rance, Dore, & Grebely, 2014) and complex 
medication regimens, including self-administered weekly injections. Treatment adherence can 
also be influenced negatively by psycho-social factors.  
 
Adherence and Psycho-social Factors – Existing Literature  
Sublette and colleagues (Sublette et al., 2015) argue that a lack of social support, language 
barriers, unstable housing, social marginalisation, discrimination and employment status play 
a role in non-adherence to HCV treatment (Manos, Michele, Chanda, Ho, Murphy, Rosemary, 
& Shvachko, Valentina, 2013; McHutchison et al., 2002). A review of the literature demonstrates 
further that non-persistence in HCV treatment is predicted by factors such as younger age, lower 
education, no or public insurance, and more severe baseline side effects (Evon et al., 2013). It is 
striking that the studies included in this review did not address the relationship between 
psychosocial factors and positive adherence. The lack of consideration given to the patient’s 
perspective in published literature is equally salient. Only one recent interview study conducted 
by Sublette et al. (2015) has looked at facilitators of HCV treatment. Phenomenological analysis 
of patient interviews identified four key themes. Firstly, fear of death and alleviating stigma and 
shame were found to motivate patients to commence HCV treatment. Secondly, provider 




information and feedback that was personalised to their needs and lifestyles was the most 
effective for improving adherence to treatment. Thirdly, social, emotional and practical support 
improved completion of the full treatment course, as did temporarily ceasing employment.  
 
The recent qualitative publication by Sublette et al. (2015) indicates that a psychological 
evidence base on HCV treatment adherence is emerging and a number of questions remain 
unanswered.  For instance, existing research is limited in two important ways:  
 
 a). Socio-cultural Context 
The aforementioned study (Sublette et al., 2015) recruited from two liver clinics in metropolitan-
based hospitals in Sydney, Australia. Healthcare in Australia is provided by both private and 
government institutions, while in Scotland the public system dominates healthcare provision. 
Research suggests that patients who have the capacity to pay for private sector facilities report 
preferring the care they receive because of shorter waiting periods, longer or more flexible 
opening hours, and better availability of staff (International Finance Corporation, 2011). This 
aspect may have influenced the nature of the cohort recruited to this study and their subsequent 
HCV treatment experience. The demographic profile of the local population is also a source of 
contrast. According to the Scottish Index of Multiple Deprivation 2012 statistics, the level of 
both income, and unemployment deprivation in Dundee city is greater than in Scotland as a 
whole. In contrast, Sydney has been ranked tenth in the world in terms of quality of living 
(Mercer Co., 2009), with workers receiving the seventh highest wage levels of any city in the 
world (Aisslinger & Kutz, 2012).  There are clear limitations in extrapolating findings from an 
Australia to a UK population. 
  
 b). Theoretical Approach 
There are additional drawbacks regarding the philosophical position adopted by Sublette et al. 
(2015). These authors used framework analysis (Ritchie, Spencer, & O’Connor, 2003) within a 
phenomenological research design to analyse interview data. While this methodology is a useful 
step in allowing us to understand the subjective lived experience of HCV treatment, it does not 
conceptualise treatment as a social process related to specific conditions, contexts, and 
contingencies. Grounded theory however, explicitly examines the relationships among these 
elements (Strauss & Corbin, 1990). This method has potentially greater utility in the field of HCV 
treatment adherence research as it can be used to generate an explanatory model upon which 





Current Study   
The current study will address the shortcomings of existing knowledge by focussing on positive 
adherence, using a grounded theory methodology, and applying this within a novel socio-
economic and treatment context. This aim will be achieved by focussing on participants 
receiving HCV treatment in Scotland. The ERADICATE Hepatitis C trial, based in Tayside, 
targets younger infected drug users for HCV treatment using combination therapy. The 
population for the study are members of the community who attend needle exchange centres, 
but are otherwise not engaged with substance misuse services. The ERADICATE trial offers 
intensive support and regular follow up by community based nurses, and uses contingency 
management to support adherence. This is a unique treatment study; which does not require 
participants to cease injecting behaviour in order to receive treatment. Historically, before the 
implementation of the Hepatitis C Action Plan for Scotland II (The Scottish Government, 2008) 
current intravenous drug use and/or having a chaotic lifestyle would have been considered a 
contraindication for antiviral therapy (see Health Protection Scotland, 2008). In contrast, the 
ERADICATE trial does not require participants to cease injecting behaviour in order to receive 
treatment. The trial has been recruiting since 2013 and over 90% of participants have adhered 
to the treatment. This is noteworthy, given that discontinuation rates in similar clinical trial 
studies range from 4-27% (Mullhall & Younossi, 2005). From both a clinical and research 
perspective, the experiences of active and former drug users are important in generating 
hypotheses about the psychological processes underlying HCV treatment adherence. This is the 
impetus behind the current study.   
 
Research Questions / Objectives: 
(Keep these focused and concise, with a maximum of five research questions).  
2) What is the principal research question / objective? (IRAS A10) 
 
To gain a qualitative understanding of positive treatment adherence for HCV based on the self-
report experience of participants who have successfully engaged in the ERADICATE trial. 
To produce a grounded theory of positive treatment adherence for HCV. 
  
3) What are the secondary research questions / objectives if applicable? 
(IRAS A11) 
 
To explore if, and how, aspects such as perceptions of the service provider and/or bio-psycho-
social factors inform positive treatment adherence for HCV, should these themes emerge from 






4) Please give a full summary of your design and methodology. It should be clear 
exactly what will happen at each stage of the project. (Relevant to IRAS A13)  
 
Research design: 
A semi-structured interview schedule will be generated and information pertaining to HCV 
treatment adherence will be gathered through open-ended questions (Reid, Flowers & Larkin, 
2005). An interview schedule will be developed in consultation with trial nurses, clinical and 
academic supervisors, as well as qualitative experts at the University of Edinburgh to gain an 
understanding of HCV treatment adherence from the service provider perspective. This strategy 
is expected to enrich the interview preparation process without compromising the neutral, 
exploratory approach to the data. Grounded theory inquires how social structures and processes 
influence how phenomena occur through a given set of social interactions (Starks & Trinidad, 
2007). Considering the perspective of trial staff is expected to enhance the grounded theory by 
recognising the dynamic relationship between patient and service provider, and the treatment 
context potentially created by this interplay.  
 
Participants: 
The population under investigation is a hard to reach, chaotic group of actively injecting intra-
venous drug users, who have little contact with services. They have little or no intention of 
changing their drug use and engage in few harm reduction measures. This group is typically 
believed to be too difficult to target for treatment. It is widely presumed that the required 
adherence is not achievable for drug users with this stereotypical profile. However, a high 
proportion of this group (91.9%) have successfully engaged in the ERADICATE Trial, after being 
identified and selected through an urban needle exchange centre. Those participants who have 
engaged in the trial and adhered to the HCV treatment regime will be the subject of this 
research.  
 
Effort will be made to include a sample of vulnerable participants, including women, 
current/former intravenous drug users, individuals who are homeless, and/or unemployed with 
a view to enhancing the conceptual generalizability of the grounded theory generated. 
 
Establishing the Research Collaboration: 
The two trial nurses were contacted initially and a meeting took place (April 2015) to gather 
more information about the HCV treatment provided by ERADICATE and the nature and 




A preliminary research planning meeting has taken place (May 2015) between the Trainee 
Clinical Psychologist / Chief Investigator (CI) for this study, both clinical supervisors, the 
ERADICATE Trial Manager, the two trial nurses and the trial Chief Investigator / Grant Holder. 
A doctoral level qualitative was proposed and discussed. The remit of the CI as a Trainee Clinical 
Psychologist was clarified. Feasibility issues around data collection and ethics requirements with 
the timeframe available were considered. A follow-up phone call was conducted with the Trial 
Manager to relay the purpose and duration of thesis project. Further research group meetings 
with all relevant parties will take place (next scheduled for July 2015).  
Procedure: 
Trial nurses will be contacted further to identify a suitable pool of participants who fit the 
inclusion criteria, and to facilitate access to participants for interview. Demographic 
information about participants collected as part of the trial including participants: age, gender, 
employment status and current injecting behaviour (if actively using intravenous drugs, or not). 
Potential participants will firstly be supplied with an information sheet by their trial nurse to 
make them fully aware of the interview purpose and procedure. They will also be supplied with 
a separate consent form and invited to return this to their trial nurse at their next clinic 
appointment the following week, if they are willing to participate. Once the consent form has 
been returned to the CI, willing participants will be contacted by phone to arrange a suitable 
time to conduct the interview, or, if appropriate will be asked by their trial nurse to attend their 
next clinic appointment one hour early, or to stay after their appointment to facilitate an 
interview. 
 
The initial procedure preceding data collection is the generation of an interview schedule which 
captures a flexible list of topics to be covered during interview (see Table I Topic Guide). This 
will be informed by current literature and further developed in consultation with trial nurses, 
and academic staff within the University. Non-leading, open-ended questions will be compiled 
and short-listed with the aid of peer review. Questions will have a broad focus that is consistent 
with the research aim. The schedule will guide a directed conversation with the overall aim of 
capturing the participant’s treatment experience as it relates to positive adherence. Interviews 
will last between 40 and 60 minutes and will be conducted privately at the trial clinic site, which 
is a long-standing hub of multi-service provision specifically for this population. All interviews 
will be audio recorded and transcribed verbatim by the researcher. For the purpose of credibility 
checking, a small number interviewees will be asked to feedback on the preliminary results of 
the grounded theory; this is expected to be highly feasible, as those who are recruited will likely 





Table I: Topic Guide 
Quality of care 
Confidence in the experience, knowledge and skill staff regarding treatment and 
drug use 
Provision of advice/general help; patient’s need for information/education  
Knowing how well the treatment is working to reduce viral load  
Getting prescriptions from trial staff 
Availability of treatment for active drug users 
Reputation of clinic and impact of this 
Psycho-social factors 
Going through treatment with my partner / friend / family member. 
Perception/meaning of stigma of HCV 
Views of my peers / family members regarding HCV 
Views of long-term benefits of treatment generally 
Influence of friends/family members regarding treatment completion 
Fears regarding HCV (death, contamination, infecting people who are important to 
me (e.g., partner, friends, children) 
Confidence in the treatment and potential for cure 
Knowing other people who have completed treatment successfully 
Motivation to engage in treatment beyond minimal course for effectiveness 
Behavioural facilitators 
Rewards for treatment (e.g., shopping vouchers, protein drinks, vouchers for 
inviting a friend). 
Access to numerous services onsite at clinic (e.g. sexual health, food parcels).  
Impact of wait to treatment  
Availability of appointments 
Frequent contact with clinic (i.e. weekly basis). 
Having appointments on the same day each week 
Convenience of location (e.g., access to public transport, car parking etc) 
Being able to contact my nurse outside of clinic appointments (e.g., having their 
mobile phone number) 
Role of offer of food and drink if waiting to be seen 
Time-limited nature of treatment 
Treatment approach 
Information on treatment; enhancing patient understanding 
Choice / treatment options 
Atmosphere in clinic; contrast with other healthcare environments/experiences 
Contact from service (active/passive) 
Communicating risks of treatment 
Therapeutic alliance 
Nature of relationship/partnership with trial staff 
Communication from/with staff 






5)  Please list the principal inclusion and exclusion criteria (IRAS A17-1 and A17-2)   
 
Inclusion criteria:  
• Male and females, aged 18 - 70 with chronic HCV positive infection. 
• Demonstrated positive adherence to HCV treatment in the ERADICATE trial by attending 
weekly clinic appointments over the minimum period recommended for medication 
effectiveness (12 - 16 weeks depending on the genotype of the virus). 
• Current or historical illicit drug use, established through drug screening (oral swab / 
screening) by trial nurses.  
• Ability to sign and date informed consent, agreeing to study participation.  
• Ability to verbally engage in a semi-structured interview conducted in English, for at least 
45 minutes.  
 
Exclusion criteria:  
• Evident medical contraindications as stipulated by the ERADICATE trial (previous 
treatment with trial specific medication, or hypersensitivity to these products, evidence of 
liver failure/carcinoma, cardiac failure). 
• Failure to demonstrate positive adherence to HCV treatment in the ERADICATE trial, as 
these participants represent a minority of participants (N=7, 8.1%) who were not able to 
continue in the trial due to death, or satisfactory treatment outcome before the minimum 
period recommended for medication effectiveness.  
• Inability to verbally engage in a semi-structured interview conducted in English. 
 
6) How will data be collected? 
If quantitative, list proposed measures and justify the use of these measures. If 
qualitative, explain how data will be collected giving reasonable detail. (Don’t just say 
‘by interviews’) 
 
Consultation will take place between the Trainee Clinical Psychologist/Clinical Investigator (CI) 
and the two ERADICATE trial nurses to determine which participants would be available and 
willing to engage with the interview study. Nurses will be able to inform the CI on demographics 
(age, gender) and other salient participant characteristics such as employment status, 
accommodation status and injecting behavior. Recruitment will take place at the city-centre 
needle exchange clinic where participants have weekly appointments with a trial nurse. Three 
clinics per week are conducted on a drop-in basis (11am – 4pm). Depending on demand, 




to recruit participants and/or collect data. Each interview will be audio taped and then 
transcribed verbatim for analysis. After each interview, novel content will be used to further 
inform the interview schedule for subsequent participants. 
 
Sample Size 
7) What sample size is needed for the research and how did you determine this?  For 
quantitative projects, outline the relevant Power calculations and the rationale for 
assuming given effect sizes. For qualitative projects, outline your reasoning for 
assuming that this sample size will be sufficient to address the study’s aims. (IRAS 
A59 and A60) 
 
Grounded theory involves recruiting participants with differing experiences of the phenomenon 
so that the complete, multiple range of constructs that constitute the theory are fully 
represented by the data (Starks & Brown-Trinidad, 2007). There will aim to be a balance of 
heterogeneity regarding the characteristics the persons invited to interview, so that the resultant 
grounded theory is supported sufficiently, but does not suffer a lack of transferability to other 
contexts. Typical grounded theory studies report sample sizes of a minimum of 10 (Starks & 
Brown-Trinidad, 2007). Therefore, to address the research question adequately this study will 
aim to recruit at least 15 participants using a non-probabilistic, purposive sampling strategy over 
a 6 month period. This sample size is comparable to a similar interview study which recruited 
20 participants with HCV from two urban liver clinics, over a 4 month period (see Sublette et 
al., 2015).  
 
8) Outline reasons for your confidence in being able to achieve a sample of at least this 
size. (e.g. by giving details of size of known available sample(s), percentage of this type 
of sample that typically participate in such studies, opinions of relevant individuals 
working in that area) 
 
Outcomes from the ERADICATE trial to date show a high rate of successful recruitment (N=86 
in the first 18 months) and a relatively low drop-out / lost to follow-up rate (combined N=7; 
8.1%), with 79 enrolled in the study currently. This study seeks to recruit less than a fifth of this 
pool of participants for interview. Recruitment to the trial will continue to be ongoing when 
data collection for this study begins in autumn 2015.  
 
Trial nurses have contact with participants who discontinue treatment with a positive viral 
response after the minimum course of medication (3 month, 6 month, annual follow-up for 3 




actively attending weekly clinic appointments beyond the minimum period for treatment 
effectiveness. Access to, and availability of the sample for the current study is deemed to be 
feasible within the timeframe available.  
 
Analysis 
9) Please describe the methods of analysis (statistical or other appropriate methods, 
e.g. for qualitative research) by which the data will be evaluated to meet the study 
objectives. (IRAS A62) 
 
Each interview will be anonymously transcribed and labelled with the date and time of the 
interview. The transcript will be formatted with a margin, allowing space for additional analysis. 
Raw data will be repeatedly reviewed in order to establish a relationship between the text and 
the research question. Grounded theory methodology will be used to generate a dense 
conceptual explanation of positive treatment adherence for HCV. The goal is to account for 
most of the variability in ideas and behaviours in a purposive sample of active drug users.  
 
The system of data analysis proposed to code the textual data is the constant comparative 
method for constructing a grounded theory (Glaser, 1978; Glaser & Strauss, 1967; Hutchinson & 
Wilson, 2001; Strauss & Corbin, 1990).  As established by a review of the literature, positive 
treatment adherence for HCV is, as yet, an ambiguous phenomenon.  Grounded theory was 
determined to be the optimal method as it seeks to uncover and understand what lies behind 
any trend about which little is yet known (Starks & Trinidad, 2007). In comparison to other 
methods, for example, Interpretive Phenomenological Analysis or Discourse Analysis, 
Grounded Theory looks for generalisability by drawing out patterns by making comparisons 
across a diverse sample of data. It is proposed to be particularly useful when trying to 
conceptualise complex change processes based on people’s self-report (Wilson, Hutchinson & 
Holzemer, 2002; Morse & Johnson, 1991).  
 
This method is sometimes considered inductive because it generates theory using a series of 
analytic steps that go on concurrently with data collection. The steps that will guide this study:  
(a) Open coding; almost each line will be taken individually and a term applied to both 
summarise and account for the participants’ language. Codes translate the possible meaning 
behind the phrases and wording of the text. Coding places each unit of data in a wider context 





(b) Categorisation; open codes will be abstracted, condensed and clustered into more abstract 
concepts and given titles representing the similar ideas contained in each. The justification and 
reasoning surrounding the choice of categories will be recorded using theoretical memos. 
(c) Theoretical comparison; open codes and categories will be evaluated together to generate an 
integrative, explanatory framework of the phenomenon under investigation.  
While numerous guidelines describe how to increase the quality of qualitative research (Mays 
& Pope, 2000), a review of existing recommendations proposes an inclusive set of evaluative 
principles denoting good qualitative research (Cohen & Crabtree, 2008). These include ethics, 
pragmatism, theory, clarity, coherence and robust methodologies in qualitative research (Cohen 
& Crabtree, 2008). From a pragmatic perspective, Mays and Pope (2000) have identified six 
techniques to operationalize these criteria practically. These are outlined and applied to the 
current study: 
 
1. Fair dealing: Purposive sampling will be used, however multiple perspectives will be 
captured as the study will seek to recruit a sample with a balance of diversity. 
Objectively valid generalisability will not be inferred on the basis of any one account. 
2. Triangulation: Multiple interviews will be conducted. Data will be compared both 
within and across interviews to ensure comprehensiveness. The resultant grounded 
theory will be reviewed by members of the ERADICATE team to further aid 
triangulation. 
3. Reflexivity: The researcher’s prior assumptions and biases will be acknowledged and 
included in the analytic process and write-up. The rationale and implications of choices 
made by the CI will be documented in a reflective journal, which will be referred to in 
the final write-up. A selection of transcripts will be second coded to support the 
credibility of the data.  
4. Member checking: The resultant grounded theory will be returned to a sample of 
participants in the trial to maximise congruence between the individuals’ intending 
meaning and the researcher’s interpretations and conclusions. 
5. Attention to negative cases: The analysis will seek to generate explanations which 
accommodate the majority of cases, while examining alternative possibilities for cases, 
which do not appear to fit with the existing data. 
6. Clarity: All interviews will be accompanied by observational notes so no data will be lost 
due to flawed recall or inaudibility of the tapes. Peer review will be used to enhance the 
clarity of the results. Extracts will be taken from the data to illustrate and substantiate 
the inferences made in the write-up. These strategies should provide a clear account of 





Project Management: Timetable 
 
10) Outline a timetable for completion of key stages of the project. (E.g. ethics 
submission, start and end of data collection, data analysis, completion of systematic 
review). 
 
 Year 2015 
 J   F  M  A  M  J   J   A  S  O  N  D 
Year 2016 
 J   F  M  A  M  J   J  A   S  O  N  D 
Year 2017 
J   F  M  A  M  J   J   A   S  O  N  D 
Research 
group mtg. 
            
 
            
 




            
 
            
 
            
 
Ethics*             
 
            
 




            
 
            
 




            
 
            
 
            
 
Analysis             
 
            
 
            
 
Write up              
 
            
 




            
 
            
 
            
 
 
* Ethics: Preparation, submission, and approval of ethics amendment to Patient Information 
Leaflet and Consent Form. 
^ Other coursework: Including a R2 Small Scale Research Project (2015) and CP2 Case 
Conceptualization (2016). 
 
Management of Risks to Project 
11)  Please summarise the main potential risks to your study, the perceived likelihood 
of occurrence of these risks and any steps you will or have taken to reduce these risks. 
Outline how you will respond to identified risks if they should occur.  
 
Recruitment: Given the chaotic nature of the population being studied, there are risks to 
accessing participants for the purpose of interview. Participants may be lost to follow-up due to 
death, or disengagement. However, the feasibility of obtaining the required sample size has been 




have completed the minimum course of treatment. To date there are 79 participants enrolled in 
the trial and recruitment is ongoing for at least the next two years.   
 
Supervisor absence: The current study will be supervised by both an academic and clinical 
supervisor. In their absence a second clinical practitioner involved in the research group will be 
available as a form of contingency. The CI has also developed links with other Clinical 
Psychology Trainees engaged in qualitative research to share expertise regarding this 
methodology.  
 
Potential distress to participants: During the interview process participants will be asked about 
their HCV status and treatment and it is possible that asking participants to focus on this acutely 
personal issue may cause some distress. The CI will use a person-centred responsive 
interviewing style to build trust and minimise the potential for upset within the conversation 
(Rubin & Rubin, 2012). The participant information sheet will direct the participant to raise any 
concerns or questions regarding the study with their trial nurse with whom they have regular 
contact. Participants will also be reminded on the information sheet that participation is 
voluntary, that they are free to withdraw at any point i.e. retract the consent for their data to be 
used and that their continuity of care will not be affected by their participation or non-
participation in the study.  
 
Multiple stakeholders: Linking with a clinical drug trial represents both a risk and significant 
opportunity for the current thesis project. The CI should liaise closely with the Trial Manager 
and nurses. Increased collaboration means decreased autonomy, as the purpose and outcome 
of the research needs to meet a mutually beneficial aim for all stakeholders. Clarity of 
communication between all involved parties and contingency planning will be of paramount 
important in carry out the research. To date one large research group meeting has taken place 
and proved a useful opportunity to build working relationships. While the CI is required 
advocate for the needs of a Trainee Clinical Psychologist, the experience of working with a 
research group is deemed to be a valuable and relevant learning opportunity which is supported 
by the CI’s Clinical Supervisors, Line Manager and Head of Service.  
 
As the trial is funded by companies in the pharmaceutical industry, conflict of interest may arise 
regarding the use of participant data. However, as stipulated in the ERADICATE trial protocol, 
ownership of the data resides with the study team and their respective collaborators (i.e. the CI 
for this study) and funders are not stated to have nay rights of access to the data. Data analysis 
and reporting is understood to be permissible for written or oral dissemination in the form of a 






12) How do you intend to report and disseminate the results of the study?  (IRAS A51) 
 
This study will be submitted in part fulfillment of Doctorate in Clinical Psychology, as such the 
thesis will be available through the University of Edinburgh library. Each participant will be 
given a written summary of the study findings. The study will be presented to the ERADICATE 
trial team, particularly the role of service provision on positive treatment adherence. The study 
will be presented at the NHS Tayside Psychological Therapies Departmental meeting. The 
related systematic review and empirical study will also be submitted to an appropriately 
identified peer-reviewed journal for consideration e.g. Qualitative Health Research, Psychology 
and Health. The study will be seek to be presented at national and international scientific 
meetings and conferences e.g. International Conference on Viral Hepatitis and Liver Diseases, 
The Viral Hepatitis Congress, European Conference on Hepatitis C and Drug Use.  
 
13) What are the anticipated benefits or implications for services of the project? (E.g. If 
this is an NHS based project, in what way(s) is the project intended to benefit the NHS?) 
 
While HCV mainly spreads through intravenous drug use, particularly sharing needles, active 
drug users are not currently offered HCV eradication treatment. This group typically leads a 
very chaotic lifestyle which makes it difficult for them to engage with services and to comply 
with the strict treatment routines and required medical follow up. The proposed study links to 
a pioneering trial which does not withhold treatment on this basis. This research seizes a 
valuable opportunity to capture the rich detailed treatment experience of active drug users in 
Scotland. This is a marginalised and stigmatised population, whose unique socio-cultural 
experience is not represented in existing literature. 
 
A technical report from Oxford University and Rand Europe Co. (Patruni & Nolte, 2013) 
demonstrates that there are significant public health benefits to lowering the pool of individuals 
with HCV infection, and that this is possible even if people are still injecting drugs. There is also 
the potential for significant savings for the NHS and significant increase in economic output 
and productivity if more people with Hepatitis C are successfully treated. They proposed that 
quadrupling treatment rates would halt the rise in projected prevalence of HCV infection in the 
UK (Patruni & Nolte, 2013). Treatment adherence is a crucial variable in treatment success. The 
process by which adherence is achieved should be therefore be understood and used to enhance 




who currently inject, or not, can be used to inform future HCV treatment trials under the remit 
of the ERADICATE team, and beyond. 
 
Evon, Golin, Fried and Keefe (2013) argue for the particular expertise of Clinical Psychologists in 
understanding, managing and evaluating the complex interplay between bio-psycho-social 
factors, antiviral treatment and HCV health outcomes. The current study explores this assertion, 
and the data from this study may support a more robust role for CPs within clinical health 
specialties such as hepatology. While CPs hold relevant clinical knowledge and skills, they can 
also contribute to health economic activity (research, policy development), where HCV is 
particularly salient concern.    
 
14)  Are there any potential costs to this project?  
Outline any potential financial costs to the project, including the justification for the 
costs (why are these necessary for the research project?) and how funding will be 
obtained for these costs (how will cost be met?).  Please separate these into potential 
costs for the University and potential costs for your NHS Health board and note that 
you should ask your NHS Health board to meet stationery, printing, postage and travel 
costs.  
 
Participants in the trial will be offered small reward, of a £5 supermarket voucher to incentivise 
them to take part in the study. Given the effectiveness of contingency management with the 
cohort so far, such remuneration is expected to significantly enhance recruitment to the study. 
Funding for this would be secured from the health board Psychology Department budget; this 
request has already been informally approved by the Head of Service.  
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17) Confirmation of Supervisors’ Approval 
I confirm that both my academic and clinical supervisors have seen and approved this 
research proposal and have both completed the supervisors’ appraisal forms below.  








Methodological Review  
 
Main Academic Thesis Supervisor’s Appraisal of Project Risk 
 
 
Supervisor’s Name: David Gillanders 
 
 
Do you consider that the project should proceed in broadly its current form? 
 (Delete as appropriate) 
 
 
Yes           
  
 
Please outline the reasons for your response. In particular, highlight any areas of 
risk to the completion of the project that have not been fully addressed within the 























Date:  8th July 2015 
My view is that this proposal outlines a useful question around understanding adherence in a 
marginalized group and a method that is capable of addressing that question. The student has 
already started to establish the necessary relationships within the research context that will 
be vital for the success of this study. The quality of thinking in terms of the methodological 
choices and procedures also seems good to me, given the first year stage if training that this 
student is at. The project appears well supported in the clinical context. My view is that it is 
feasible, that this student will be able to deliver it and that it will lead to new knowledge that 









Appendix III: Sample Line-by-Line Coding  
Interview #12: Gemma – Segment 05:38 – 09:54 
I: I’m wondering what was good about that aspect [talking 
to the nurses], what was helpful? 
G: Ehm… I spose because I’m getting’ it out an’ not 
keepin’ it all in an’ they’re listin’ to you an’… yeh they were 
easy to speak to  
I: They were easy to speak to? 
G: Yeh 
I: I guess was there anything else you felt about them or 
about this place? 
G: Yeh they were really friendly they make ya they’re 
really friendly an’ tha’ they don’ make you don’t feel 
awkward abou’ gettin’ the treatment or stuff like tha’ 
because they they’re dead nice abou’ it yeh… they make 
you feel really .. they make you feel good they’re always 
chatty an’ nice wi’ ya  they’ were wi’ me so  
I: You felt listened to and able to share with the nurse. 
G: Yeh you did yeh you really did they were jus’ good to 
speak to I still speak to [name of nurse] an’ tha’ if I see 
them no they were they were really good [whispers] 
stealin’ a biscuit [takes a biscuit] 
I: Of course, go ahead. And you mentioned that you’d 
been coming to the [name of Centre] for a while before 
actually starting the trial? 
G: Years 
I: A few years, wow, so did that make a difference? 
G: …probably ehm cos’ I was familiar wi’ comin’ in an’ out 
I: It was somewhere you were familiar with? 
G: Yeh an’ I know it’s abou’ it’s where you used to get yer 
needles an’ stuff so yer not sorta judged here cos you 
know wha’ yer here for if ya know wha’ I mean tha’ is 
important  
I: Something that’s come up with other people I’ve spoken 
to is that people felt different coming to this centre rather 
 
 
Talking and sharing was helpful 
Feeling listened to 
 
 




Feeling comfortable with nurses 
Linking kindness to ease with treatment  




Experienced benefit from talking 






Attended centre for years 
 
Previous familiarity with setting was 
influential  
 
Used needle exchange facility  










than going to hospital. Would you have any thoughts 
about that? 
G: I would rather come here than go to the hospital just 
the the sp.. they’re more down to earth they’re more nice 
they’re a lot nicer wi’ ya like the hospital’s dead formal an’ 
then you you feel .. at ease here you didn’ feel 
embarrassed or tha’ here like if I was at the hospital I 
would feel embarrassed an’ ashamed an’ stuff eh but here 
I didn’ cos I know that’s the.. work wi’ I know the hospital 
work wi’ everybody but this is all they do an’ they’re just 
really nice you didn’ feel any awkwardness or tha’ 
somehow so 
I: Have you had different experiences in hospital? 
G: When I went to hospital when I had DVT yeh you feel 
horrible it’s not nice it’s not good 
I: What was it about it? 
G: Jus’ the people the way they… I mean when I got ma’ 
x-ray you see the staff all lookin’ at one another like ‘ken 
jus’ wi’ the eyes an’ stuff an’ you know it’s abou’ what’s 
on .. it’s jus’ not you jus’ dinnae feel good eh well I didn’ if 
I was here gettin’ the x-ray done they would be speakin’ 
to me and sayin’ it’s jus’ it’s jus’ different you jus’ don’t feel 
like tha’ I jus’ didn’ like the hospital at all 
I: Do you think if the ERADICATE treatment was offered 
at the hospital you would’ve.. [cut-off] 
G: [shakes head] No no only done it cos it was here 
I: Only because it was here, so that was really important? 
G: Ah-huh as soon as you get to it I knew the place cos I 
used to come anyway if I had to start tha’ at the hospital I 
don’t think I woulda went all the way through probably 
woulda went the first once or something I wouldn’ went 
back so yeh it is important where ya get it  
 
 
Preferring centre to hosp. 
Contrasting interpersonal manner of staff 
Hosp. is more formal 
 
Feeling embarrassed, ashamed at hosp. 
Feeling more at ease at centre 
Specialist IDU services provide more 
sensitive care than general 
Linking comfort to staff experience, 
approach 
 
Previous negative experience at hosp. 
 
 
Perceived stigmatising body language 
from hosp. staff 
Feeling judged for medical hx, IDU 
Contrasting  staff approach at centre 
Being talked to, procedures explained  




Engagement strongly linked to location 
 
Previous familiarity with centre as key  
Predicting disengagement f/m hosp. 
Would not have engaged fully 





Appendix IV: Sample Axial Coding 







Appendix V. Sample Journal Entries 
[Excerpt] Entry #29. 06/06/15 - Socio-cultural context and researcher responsibility. 
The status of my participants in society is one of social and economic disadvantage and 
deprivation. They are the “down-trodden” - people that are unseen, unheard and unwanted. I 
just came across an article talking about a sculpture exhibition in London. It was a plaster-cast 
of a human figure wrapped in a bin bag hunched over, and placed on the street. The title was 
“Left Out”; what a moving and visceral depiction of homelessness. These images8 (see below) 
are such powerful metaphor for degradation, shame, worthlessness. What a visceral way of 
depicting our perception of people on the street; how it’s so much easier to see a bag of rubbish 
than a human being, a person, people like my participants. And while this is art, my eyes fill up 
recalling “Jack”, the man that who in front of me wearing a black plastic bag under his clothes, 
knowing that when he left the interview room he would sleep on the street. 
 
And what is the role of research within Clinical Psychology in society, in this context around 
PWID and homeless populations? The argument is that by only giving these people a voice 
through the medium of research, and doing so in a discreet and sanitised way for the purposes 
of journal submission, that we are complicit in maintaining an “us” and “them”. As researchers 
we are in a position of power; as a university educated, middle-class, professional I am incredibly 
privileged be the one sitting on my sid1e of the table, asking the questions. In a way, I “allowed” 
people to speak about their experience. Does research with vulnerable group implicitly reinforce 
their “otherness” and “less than-ness”? Were the moments of misattunement, or not feeling truly 





able to identify with my participant’s experiences and their internal world, a kind of 
transference, reflecting how they feel? Is this related to a theme of connection-disconnection?  
[Excerpt] Entry #33. 29/07/15 – Post S/v w. DG. (#12) - Macro-level interpretations in 
qualitative analysis. 
Interesting discussion with DG around the tension between clinical psychology as an empirical, 
positivist science and the social constructivist approach of grounded theory. Important to 
remember that the dichotomy is false and inaccurate. The purpose of qualitative research is not 
to establish an objective truth, but it is about making intentional choices about what I’m doing 
and why I’m doing it that way. Is it useful? How? Qualitative research be hugely helpful in 
developing quantitative hypotheses and in this way they are two sides of the same coin.  
While staying faithful to the empirical process is undoubtedly important, the finished article is 
read and heard, how findings translate to practice is equally, if not more important than using 
lots of jargon in the description. We need to be conscious of capturing and translating the 
richness of the data in the reporting and analysis – staying grounded in the data. As long as we 
write consciously for a readership situated in mainstream psychological science, we can navigate 






Appendix VI: Participant Consent Form 
 
Study Ref.: 2012GA01       Participant Id : ……… 
Title of Study: Exploring Treatment Experience within the ERADICATE Trial 
Name of Researcher: Chief Investigator: Prof. John Dillon; Study Investigator: Maeve 
Butler. 
Please initial box  
1. I confirm that I have read the information sheet dated.................... (version............) for 
the above study. I have had the opportunity to consider the information, ask questions 
and have had these answered satisfactorily. 
 
2. I understand that my participation is voluntary and that I am free to withdraw at any time 
without giving any reason, without my medical care, treatment within the ERADICATE 
trial, or legal rights being affected. 
 
3. I understand that relevant sections of my data collected during the study may be looked 
at by the research team or the regulatory authorities, NHS Tayside, or the University of 
Dundee (or their appointed third party), where it is relevant to my taking part in this study. 
I give permission for these Individuals to have access to my data. 
 
4. I understand that my interview will be audio recorded and transcribed by members of 
NHS Tayside. I give permission for these Individuals to have access to my data. 
 
5. I understand that the data collected about me in this study will be used to support 
other research in the future, and may be shared anonymously with other researchers. 
 
OPTIONAL 
6. I understand that I may be contacted again to give feedback on the conclusions drawn 
by the researcher in relation to this study. 
 
7. I agree to take part in the above study. 
           
Name of Participant   Date   Signature 
           




Appendix VII: SR Quality Criteria 
 
Quality Criteria for Systematic Review 
Question: What are the factors associated with staff turnover in substance misuse 
services? 
 
Title and Abstract 
1. Statement of purpose: 
 
2 points Title clearly indicates the study design and variables being examined. 
Abstract provides a clear, succinct summary of method and salient 
outcomes.   
1 points  Title does not clearly indicate the study design and variables being 
examined. Abstract provides a partial/unclear summary of method and 
salient outcomes.   
0 points / NA Not addressed / reported / applicable. 
 
Introduction 
2. Rationale & objectives: 
 
3 points Primary research question is clearly described and substantiated by a 
clear, theoretically informed a priori hypotheses.  
2 points Primary research question is adequately described. Hypotheses are 
proposed with partial clarity. The theoretical supposition informing the 
hypothesis is not theoretically robust, is unclear in the context of the 
study, or only describes minimal background literature.  
1 point Primary research question is poorly or insufficiently described. 
Hypotheses are not stated, or not informed by theory, or supporting 
literature, or evidence has been misunderstood/misappropriated leading 
to unfounded inferences.  





3 points Study design is clearly described, and appropriately addresses the 
association between variables of interest (e.g. correlational, cross-
sectional, longitudinal).  
2 points Study design is adequately described, but only partially addresses the 
association between variables of interest, but this can be inferred (e.g. 
group comparison).  
1 point Study design is poorly or insufficiently described, without reference to 
the association between variables of interest (e.g. case study).  












4. Setting and recruitment: 
 
3 points Setting (e.g. organisation structure – inpatient, outpatient, and service 
provision – intensive, methadone maintenance), location and 
recruitment method (e.g. inclusion criteria, periods of recruitment, 
follow-up, and data collection) are clearly described and appropriate. 
2 points Inclusion criteria, setting and recruitment method are adequately 
described.  
1 point Inclusion criteria, setting and recruitment method are poorly or 
insufficiently described, with significant omissions. 
0 points / NA Not addressed / reported / applicable. 
 
5. Data source: 
 
3 points Data source is clearly described (e.g. who provided what proportion of 
turnover information and where the information was originally logged). 
Data is cross-referenced with at least one other source, if appropriate 
(e.g. secondary analysis).  
2 points Data source is adequately described but incomplete, and is cross-
referenced, if appropriate. 
1 point Data source is poorly or insufficiently described, and is not cross-
referenced, if appropriate.   




3 points All variables of interest (outcomes, predictors, modifiers) are clearly 
defined and operationalised appropriately. The outcome variable of 
interest, staff turnover is expressed as a rate, for which the formula used 
is described.  
2 points Variables are adequately defined operationalised. Staff turnover is 
operationalised as a rate / numerically, but the formula used is not 
described.   
1 point Variables are not defined or poorly or insufficiently operationalised. Staff 
turnover is not expressed numerically.  
0 points / NA Not addressed / reported / applicable. 
 
7. Reliability and validity of measures: 
 
3 points Standardised/objective measures are used to assess factors associated 
with staff turnover and have good internal reliability and validity. 
2 points Measures used to assess factors associated with staff turnover have 
adequate internal reliability and validity.  
1 point Measures used to assess factors associated with staff turnover have 
poor internal reliability and validity, or have been developed for the 
purpose of the study.   








8. Statistical methods: 
 
2 points Method of statistical analysis, and rational is clearly described and 
appropriate. 
1 points Method of statistical analysis, and/or rational is not clearly described, or 
is inappropriate.  
0 points / NA Not addressed / reported / applicable. 
 
Results 
9. Descriptive data: 
 
3 points Sample is clearly described, including full characteristics of staff (e.g. 
education, professional grouping, years of experience, tenure, annual 
salary) and demographics (age and gender). 
2 points Sample is adequately described, with some incomplete characteristics 
of staff and/or demographics. 
1 point Sample is poorly or insufficiently described, with significant omissions 
regarding characteristics of staff and/or demographics. 
0 points / NA Not addressed / reported / applicable. 
 
10. Power of sample size: 
 
3 points Power calculation is reported and sample size adequately meets the 
recommendation for the analysis conducted, or comments on being 
underpowered.  
2 points Power calculation is not reported, but sample size is estimated to 
adequately support the analysis conducted.  
1 point Power calculation is not reported, and sample size is not estimated to 
support the analysis conducted, but this is commented on.   
0 points / NA Not addressed / reported / applicable. 
 
11. Representativeness of sample: 
 
2 points Number of individuals eligible for inclusion, and number who were 
included (i.e. who responded) are reported. Reasons for non-inclusion / 
non-response are clearly described.  
1 point Number of individuals eligible for inclusion is not reported, but number 
who were included is reported. Reasons for non-inclusion / non-
response are not clearly described.  
0 points / NA Not addressed / reported / applicable. 
 
12.  Outcome data: 
 
3 points Outcomes from statistical analysis (relevant descriptive and inferential 
data) are clearly reported. The statistical significant of associations 
between variable is reported.  
2 point Outcomes from statistical analysis are adequately reported, though 
maybe unclear.  
1 point Outcomes from statistical analysis are poorly or insufficiently reported, 
and are unclear. 





13. Treatment of confounds: 
 
2 points Confounding variables clearly identified and adjusted for. Unadjusted 
estimates and, if applicable, confounder-adjusted estimates and their 
precision (e.g., 95% confidence interval) are provided.  
1 point Some potientially confounding variables are identified and controlled for 
in part of the analysis, but full description is not provided.  




2 points Attrition (drop-out) rate and explanation is clearly described.  
1 point Attrition rate is stated but explanation is poor, or not described.  
0 points / NA Not addressed / reported / applicable. 
 
15.  Missing data: 
 
2 points Missing data, and handling in analysis is clearly reported. Robust steps 
made to minimise bias.  
1 point Missing data is adequately reported, but unclear handling in analysis. 
Some steps made to minimise bias.  
0 points / NA Not addressed / reported / applicable. 
 
Discussion 
16. Key results: 
 
3 points Results are clearly summarised and address the association between 
variables as indicated by the research question/hypotheses.   
2 points Results are adequately summarised; the association between variables 
is not fully addressed, but this can be inferred.  
1 point Results are poorly summarised; the association between variables is not 
addressed. 




2 points Limitations (e.g. bias, imprecision) and implications for findings are 
clearly described.  
1 points Limitations and implications for findings are adequately described.  
0 points Limitations and implications for findings are poorly or insufficiently 
described.  
0 points / NA Not addressed / reported / applicable. 
 
18. Interpretation and generalisability: 
 
2 points Conclusions and overall interpretation of results are appropriately 
cautious and consider objectives, limitations, analyses, and existing 
evidence. The generalisability of results is commented on.  
1 point Conclusions and overall interpretation of results are not appropriately 
cautious and/or do not consider objectives, limitations, analyses, and 
existing evidence. The generalisability of results is not commented on.  







1 points Source of funding and role of funders in study described and, if 
applicable, description of the original study on which on which the article 
is based.   
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Dr John Dillon  
Ninewells Hospital  
Dundee  
DD1 9SY  
  
Dear Dr Dillon  
  
Study title:  
REC reference:  
Protocol number:  
Amendment number:  
Amendment date:  
IRAS project ID:  
  
Tayside Medical Science 
Centre   
Residency Block Level 3  
George Pirie Way  
Ninewells Hospital and 
Medical School  
Dundee DD1 9SY  
Date:                9 December  2015  
Your Ref:  
Our Ref:           AG/12/ES/0071 
Enquiries to:     Arlene Grubb  
  Direct Line:      01382 383848  
Eradicate Hepatitis C Virus- a pilot of treatment as 
prevention in active drug users (ERADICATE HCV)  
12/ES/0071  
version 1 03/08/2012 
AM04(REC reference 
only)  
18 November 2015  
112710  
  
The above amendment was reviewed [at the meeting of the Sub-Committee 
held on 03 and 08 December 2015 by the Sub-Committee in correspondence.   
  
Ethical opinion  
  
The members of the Committee taking part in the review gave a favourable 
ethical opinion of the amendment on the basis described in the notice of 
amendment form and supporting documentation.  
  
Approved documents  
The documents reviewed and approved at the meeting were:  
  
Document    Version   Date    
Covering letter on headed paper      18 November 2015   
Notice of Substantial Amendment (non-CTIMP)   AM04   18 November 2015   




Other [CV - Maeve Butler]      20 August 2015   
Participant consent form   1.0   02 November 2015   
Participant information sheet (PIS)   1.0   02 November 2015   
Research protocol or project proposal   1.0   02 November 2015   
  
Membership of the Committee  
  
The members of the Committee who took part in the review are listed on the 
attached sheet.  
  
R&D approval  
  
All investigators and research collaborators in the NHS should notify the R&D 
office for the relevant NHS care organisation of this amendment and check 
whether it affects R&D approval of the research.  
  
Statement of compliance  
  
The Committee is constituted in accordance with the Governance 
Arrangements for Research Ethics Committees and complies fully with the 
Standard Operating Procedures for Research Ethics Committees in the UK.  
  
We are pleased to welcome researchers and R & D staff at our NRES 
committee members’ training days – see details at http://www.hra.nhs.uk/hra-
training/   
  
12/ES/0071:   Please quote this number on all correspondence  
  
Yours sincerely  
  
  
For Dr Anthony Davis  
Vice Chair  
  





List of names and professions of members who took part in the 
review  
Copy to:   Mrs Liz Coote, NHS Tayside  
  





Attendance at Sub-Committee of the REC meeting on 03 
December 2015  
  
   
Committee Members:   
  
Name    Profession    Present     Notes    
Dr Anthony Davis   Consultant  
Anaesthetist   
Yes     Expert, Vice Chair   
Dr Stuart Paterson   Consultant Physician   Yes     Expert   
   
Also in attendance:   
  
Name    Position (or reason for attending)    
Mrs Lorraine Reilly   Senior Co-ordinator   
   
Written comments received from:   
  
Name    Position   
Dr Anthony Davis   Consultant Anaesthetist   
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Thank you for registering the above research project with the Department of 
Clinical and Health Psychology Ethics Research Panel. I can confirm that application 
submitted to NHS R&D panel been reviewed and was approved as meeting 
university requirements.  
 
Should there be any change to the research protocol it is important that you alert us 





Angus MacBeth,  
Ethics Tutor, Clinical Psychology  
SCHOOL of HEALTH IN SOCIAL SCIENCE 
CLINICAL AND HEALTH PSYCHOLOGY 
 
The University of Edinburgh 
Medical School 
Doorway 6, Teviot Place 
Edinburgh EH8 9AG 
 
Telephone 0131 651 3969 




Appendix IX: Author Guidelines (relevant extracts) 
 
Harm Reduction Journal 
Preparing your manuscript: The information below details the section headings that you should 
include in your manuscript and what information should be within each section. Please note that your 
manuscript must include a 'Declarations' section including all of the subheadings (please see below for 
more information) 
Title page: The title page should: 
• present a title that includes, if appropriate, the study design e.g.: 
o "A versus B in the treatment of C: a randomized controlled trial", "X is a risk factor for Y: a case control 
study", "What is the impact of factor X on subject Y: A systematic review" 
o or for non-clinical or non-research studies a description of what the article reports 
• list the full names, institutional addresses and email addresses for all authors 
o if a collaboration group should be listed as an author, please list the Group name as an author. If you 
would like the names of the individual members of the Group to be searchable through their individual 
PubMed records, please include this information in the “Acknowledgements” section in accordance 
with the instructions below 
• indicate the corresponding author 
Abstract: The Abstract should not exceed 350 words. Please minimize the use of abbreviations and do 
not cite references in the abstract. Reports of randomized controlled trials should follow 
the CONSORT extension for abstracts. The abstract must include the following separate sections: 
• Background: the context and purpose of the study 
• Methods: how the study was performed and statistical tests used 
• Results: the main findings 
• Conclusions: brief summary and potential implications 
• Trial registration: If your article reports the results of a health care intervention on human participants, 
it must be registered in an appropriate registry and the registration number and date of registration 
should be in stated in this section. If it was not registered prospectively (before enrollment of the first 
participant), you should include the words 'retrospectively registered'. See our editorial policies for 
more information on trial registration 
Keywords: Three to ten keywords representing the main content of the article. 
Background: The Background section should explain the background to the study, its aims, a summary 
of the existing literature and why this study was necessary or its contribution to the field. 
Methods: The methods section should include: 
• the aim, design and setting of the study 
• the characteristics of participants or description of materials 
• a clear description of all processes, interventions and comparisons. Generic drug names should generally 
be used. When proprietary brands are used in research, include the brand names in parentheses 




Results: This should include the findings of the study including, if appropriate, results of statistical 
analysis which must be included either in the text or as tables and figures. 
Discussion: This section should discuss the implications of the findings in context of existing research 
and highlight limitations of the study. 
Conclusions: This should state clearly the main conclusions and provide an explanation of the 
importance and relevance of the study reported. 
List of abbreviations: If abbreviations are used in the text they should be defined in the text at first use, 
and a list of abbreviations should be provided. 
Declarations: All manuscripts must contain the following sections under the heading 'Declarations': 
• Ethics approval and consent to participate 
• Consent for publication 
• Availability of data and material 
• Competing interests 
• Funding 
• Authors' contributions 
• Acknowledgements 
• Authors' information (optional) 
Please see below for details on the information to be included in these sections. If any of the sections 
are not relevant to your manuscript, please include the heading and write 'Not applicable' for that section. 
 
Ethics approval and consent to participate: Manuscripts reporting studies involving human 
participants, human data or human tissue must: 
• include a statement on ethics approval and consent (even where the need for approval was waived) 
• include the name of the ethics committee that approved the study and the committee’s reference number 
if appropriate. If your manuscript does not report on or involve the use of any animal or human data or 
tissue, please state “Not applicable” in this section.] 
Competing interests: All financial and non-financial competing interests must be declared in this 
section. See our editorial policies for a full explanation of competing interests. If you are unsure whether 
you or any of your co-authors have a competing interest please contact the editorial office. Please use 
the authors initials to refer to each author's competing interests in this section. If you do not have any 
competing interests, please state "The authors declare that they have no competing interests" in this 
section. 
Funding: All sources of funding for the research reported should be declared. The role of the funding 
body in the design of the study and collection, analysis, and interpretation of data and in writing the 
manuscript should be declared. 
Authors' contributions: The individual contributions of authors to the manuscript should be specified 
in this section. Guidance and criteria for authorship can be found in our editorial policies. Please use 
initials to refer to each author's contribution in this section, for example: "FC analyzed and interpreted 
the patient data regarding the hematological disease and the transplant. RH performed the histological 
examination of the kidney, and was a major contributor in writing the manuscript. All authors read and 
approved the final manuscript." 
Acknowledgements: Please acknowledge anyone who contributed towards the article who does not 
meet the criteria for authorship including anyone who provided professional writing services or 
materials. Authors should obtain permission to acknowledge from all those mentioned in the 
Acknowledgements section. See our editorial policies for a full explanation of acknowledgements and 




section. Group authorship (for manuscripts involving a collaboration group): if you would like the 
names of the individual members of a collaboration Group to be searchable through their individual 
PubMed records, please ensure that the title of the collaboration Group is included on the title page and 
in the submission system and also include collaborating author names as the last paragraph of the 
“Acknowledgements” section. Please add authors in the format First Name, Middle initial(s) (optional), 
Last Name. You can add institution or country information for each author if you wish, but this should 
be consistent across all authors. Please note that individual names may not be present in the PubMed 
record at the time a published article is initially included in PubMed as it takes PubMed additional time 
to code this information. 
Authors' information: This section is optional. You may choose to use this section to include any 
relevant information about the author(s) that may aid the reader's interpretation of the article, and 
understand the standpoint of the author(s). This may include details about the authors' qualifications, 
current positions they hold at institutions or societies, or any other relevant background information. 
Please refer to authors using their initials. Note this section should not be used to describe any competing 
interests. 
 
Endnotes: Endnotes should be designated within the text using a superscript lowercase letter and all 
notes (along with their corresponding letter) should be included in the Endnotes section. Please format 
this section in a paragraph rather than a list. 
 
References: All references, including URLs, must be numbered consecutively, in square brackets, in 
the order in which they are cited in the text, followed by any in tables or legends. The reference numbers 
must be finalized and the reference list fully formatted before submission. Examples of the BioMed 
Central reference style are shown below. Please ensure that the reference style is followed precisely. 
See our editorial policies for author guidance on good citation practice.  
Web links and URLs: All web links and URLs, including links to the authors' own websites, should be 
given a reference number and included in the reference list rather than within the text of the manuscript. 
They should be provided in full, including both the title of the site and the URL, as well as the date the 
site was accessed, in the following format: The Mouse Tumor Biology Database. 
http://tumor.informatics.jax.org/mtbwi/index.do. Accessed 20 May 2013. If an author or group of 




• Figures should be provided as separate files, not embedded in the main manuscript file. 
• Each figure of a manuscript should be submitted as a single file that fits on a single page in portrait 
format. 
• Tables should NOT be submitted as figures but should be included in the main manuscript file. 
• Multi-panel figures (those with parts a, b, c, d etc.) should be submitted as a single composite file that 
contains all parts of the figure. 
• Figures should be numbered in the order they are first mentioned in the text, and uploaded in this order. 
• Figures should be uploaded in the correct orientation. 
• Figure titles (max 15 words) and legends (max 300 words) should be provided in the main manuscript, 
not in the graphic file. 
• Figure keys should be incorporated into the graphic, not into the legend of the figure. 
• Each figure should be closely cropped to minimize the amount of white space surrounding the 
illustration. Cropping figures improves accuracy when placing the figure in combination with other 
elements when the accepted manuscript is prepared for publication on our site. For more information 
on individual figure file formats, see our detailed instructions. 
• Individual figure files should not exceed 10 MB. If a suitable format is chosen, this file size is adequate 




Figure file types 
We accept the following file formats for figures: 
• EPS (suitable for diagrams and/or images) 
• PDF (suitable for diagrams and/or images) 
• Microsoft Word (suitable for diagrams and/or images, figures must be a single page) 
• PowerPoint (suitable for diagrams and/or images, figures must be a single page) 
Figure size and resolution 
Figures are resized during publication of the final full text and PDF versions to conform to the BioMed 
Central standard dimensions, which are detailed below. 
Figures in the final PDF version: 
• width of 85 mm for half page width figure 
• width of 170 mm for full page width figure 
• maximum height of 225 mm for figure and legend 
• image resolution of approximately 300 dpi (dots per inch) at the final size 
Figures should be designed such that all information, including text, is legible at these dimensions. All 
lines should be wider than 0.25 pt when constrained to standard figure widths. All fonts must be 
embedded. 
Preparing tables 
• Tables should be numbered and cited in the text in sequence using Arabic numerals (i.e. Table 1, Table 
2 etc.). 
• Tables less than one A4 or Letter page in length can be placed in the appropriate location within the 
manuscript. 
• Tables larger than one A4 or Letter page in length can be placed at the end of the document text file. 
Please cite and indicate where the table should appear at the relevant location in the text file so that the 
table can be added in the correct place during production. 
• Larger datasets, or tables too wide for A4 or Letter landscape page can be uploaded as additional files. 
Please see [below] for more information. 
• Tabular data provided as additional files can be uploaded as an Excel spreadsheet (.xls ) or comma 
separated values (.csv). Please use the standard file extensions. 
• Table titles (max 15 words) should be included above the table, and legends (max 300 words) should 
be included underneath the table. 
• Tables should not be embedded as figures or spreadsheet files, but should be formatted using ‘Table 
object’ function in your word processing program. 
• Color and shading may not be used. Parts of the table can be highlighted using superscript, numbering, 
lettering, symbols or bold text, the meaning of which should be explained in a table legend. 
• Commas should not be used to indicate numerical values. 
 
